777 results on '"Hasle, H."'
Search Results
2. OP0034 A NOVEL SERUM CALPROTECTIN (MRP8/14) PARTICLE ENHANCED IMMUNO-TURBIDIMETRIC ASSAY (SCAL TURBO) HELPS TO DIFFERENTIATE SJIA FROM OTHER DISEASES IN ROUTINE CLINICAL LABORATORY SETTINGS
- Author
-
Foell, D., primary, Saers, M., additional, Park, C., additional, Brix, N., additional, Glerup, M., additional, Kessel, C., additional, Wittkowski, H., additional, Hinze, C., additional, Berntson, L., additional, Fasth, A., additional, Nielsen, S., additional, Nordal, E., additional, Rygg, M., additional, Hasle, H., additional, Herlin, T., additional, Holzinger, D., additional, Niederberger, C., additional, and Schlüter, B., additional
- Published
- 2023
- Full Text
- View/download PDF
3. Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: THE EVOLVING GENETIC LANDSCAPE OF PEDIATRIC MDS-EB
- Author
-
Erlacher, M., primary, Yoshimi, A., additional, Stasik, S., additional, Ramamoorthy, S., additional, Lebrecht, D., additional, Noellke, P., additional, Goehring, G., additional, De Haas, V., additional, Starý, J., additional, Masetti, R., additional, Ussowicz, M., additional, Barzilai-Birenboim, S., additional, De Moerloose, B., additional, Kállay, K., additional, Buechner, J., additional, Dworzak, M., additional, Catala, A., additional, Hasle, H., additional, Schmugge, M., additional, Polychronopoulou, S., additional, Boďová, I., additional, Jahnukainen, K., additional, Smith, O., additional, Kavcic, M., additional, Turkiewicz, D., additional, Kjollerstrom, P., additional, Locatelli, F., additional, Wlodarski, M., additional, Thiede, C., additional, Strahm, B., additional, and Niemeyer, C., additional
- Published
- 2023
- Full Text
- View/download PDF
4. Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study
- Author
-
Klein, K, Beverloo, H, Zimmermann, M, Raimondi, S, von Neuhoff, C, de Haas, V, van Weelderen, R, Cloos, J, Abrahamsson, J, Bertrand, Y, Dworzak, M, Fynn, A, Gibson, B, Ha, S, Harrison, C, Hasle, H, Elitzur, S, Leverger, G, Maschan, A, Razzouk, B, Reinhardt, D, Rizzari, C, Smisek, P, Creutzig, U, Kaspers, G, Klein K., Beverloo H. B., Zimmermann M., Raimondi S. C., von Neuhoff C., de Haas V., van Weelderen R., Cloos J., Abrahamsson J., Bertrand Y., Dworzak M., Fynn A., Gibson B., Ha S. -Y., Harrison C. J., Hasle H., Elitzur S., Leverger G., Maschan A., Razzouk B., Reinhardt D., Rizzari C., Smisek P., Creutzig U., Kaspers G. J. L., Klein, K, Beverloo, H, Zimmermann, M, Raimondi, S, von Neuhoff, C, de Haas, V, van Weelderen, R, Cloos, J, Abrahamsson, J, Bertrand, Y, Dworzak, M, Fynn, A, Gibson, B, Ha, S, Harrison, C, Hasle, H, Elitzur, S, Leverger, G, Maschan, A, Razzouk, B, Reinhardt, D, Rizzari, C, Smisek, P, Creutzig, U, Kaspers, G, Klein K., Beverloo H. B., Zimmermann M., Raimondi S. C., von Neuhoff C., de Haas V., van Weelderen R., Cloos J., Abrahamsson J., Bertrand Y., Dworzak M., Fynn A., Gibson B., Ha S. -Y., Harrison C. J., Hasle H., Elitzur S., Leverger G., Maschan A., Razzouk B., Reinhardt D., Rizzari C., Smisek P., Creutzig U., and Kaspers G. J. L.
- Abstract
Background: In addition to treatment response, cytogenetic and molecular aberrations are the most important prognostic factors in children with de novo acute myeloid leukemia (AML). However, little is known about cytogenetics at the time of relapse. Methods: This international study analyzed the prognostic value of cytogenetic profiles and karyotypic changes in pediatric relapsed AML in relation to the probability of event-free (pEFS) and overall survival (pOS). For this purpose, cytogenetic reports from all patients registered on the Relapsed AML 2001/01 Study were reviewed and classified. Results: Cytogenetic information at relapse was available for 403 (71%) of 569 registered patients. Frequently detected aberrations at relapse were t(8;21)(q22;q22) (n = 60) and inv(16)(p13.1q22)/t(16;16)(p13.1;q22) (n = 24), both associated with relatively good outcome (4-year pOS 59% and 71%, respectively). Monosomy 7/7q−, t(9;11)(p22;q23), t(10;11)(p12;q23), and complex karyotypes were associated with poor outcomes (4-year pOS 17%, 19%, 22%, and 22%, respectively). Of 261 (65%) patients for whom cytogenetic data were reliable at both diagnosis and relapse, pEFS was inferior for patients with karyotypic instability (n = 128, 49%), but pOS was similar. Unstable karyotypes with both gain and loss of aberrations were associated with inferior outcome. Early treatment response, time to relapse, and cytogenetic profile at time of relapse were the most important prognostic factors, both outweighing karytoypic instability per se. Conclusion: The cytogenetic subgroup at relapse is an independent risk factor for (event-free) survival. Cytogenetic assessment at the time of relapse is of high importance and may contribute to improved risk-adapted treatment for children with relapsed AML.
- Published
- 2022
5. European standard clinical practice - Key issues for the medical care of individuals with familial leukemia
- Author
-
Förster, A, Davenport, C, Duployez, N, Erlacher, M, Ferster, A, Fitzgibbon, J, Göhring, G, Hasle, H, Jongmans, M, Kolenova, A, Kronnie, G, Lammens, T, Mecucci, C, Mlynarski, W, Niemeyer, C, Sole, F, Szczepanski, T, Waanders, E, Biondi, A, Wlodarski, M, Schlegelberger, B, Ripperger, T, Förster, Alisa, Davenport, Claudia, Duployez, Nicolas, Erlacher, Miriam, Ferster, Alina, Fitzgibbon, Jude, Göhring, Gudrun, Hasle, Henrik, Jongmans, Marjolijn C, Kolenova, Alexandra, Kronnie, Geertruijte, Lammens, Tim, Mecucci, Cristina, Mlynarski, Wojciech, Niemeyer, Charlotte M, Sole, Francesc, Szczepanski, Tomasz, Waanders, Esmé, Biondi, Andrea, Wlodarski, Marcin, Schlegelberger, Brigitte, Ripperger, Tim, Förster, A, Davenport, C, Duployez, N, Erlacher, M, Ferster, A, Fitzgibbon, J, Göhring, G, Hasle, H, Jongmans, M, Kolenova, A, Kronnie, G, Lammens, T, Mecucci, C, Mlynarski, W, Niemeyer, C, Sole, F, Szczepanski, T, Waanders, E, Biondi, A, Wlodarski, M, Schlegelberger, B, Ripperger, T, Förster, Alisa, Davenport, Claudia, Duployez, Nicolas, Erlacher, Miriam, Ferster, Alina, Fitzgibbon, Jude, Göhring, Gudrun, Hasle, Henrik, Jongmans, Marjolijn C, Kolenova, Alexandra, Kronnie, Geertruijte, Lammens, Tim, Mecucci, Cristina, Mlynarski, Wojciech, Niemeyer, Charlotte M, Sole, Francesc, Szczepanski, Tomasz, Waanders, Esmé, Biondi, Andrea, Wlodarski, Marcin, Schlegelberger, Brigitte, and Ripperger, Tim
- Abstract
Although hematologic malignancies (HM) are no longer considered exclusively sporadic, additional awareness of familial cases has yet to be created. Individuals carrying a (likely) pathogenic germline variant (e.g., in ETV6, GATA2, SAMD9, SAMD9L, or RUNX1) are at an increased risk for developing HM. Given the clinical and psychological impact associated with the diagnosis of a genetic predisposition to HM, it is of utmost importance to provide high-quality, standardized patient care. To address these issues and harmonize care across Europe, the Familial Leukemia Subnetwork within the ERN PaedCan has been assigned to draft an European Standard Clinical Practice (ESCP) document reflecting current best practices for pediatric patients and (healthy) relatives with (suspected) familial leukemia. The group was supported by members of the German network for rare diseases MyPred, of the Host Genome Working Group of SIOPE, and of the COST action LEGEND. The ESCP on familial leukemia is proposed by an interdisciplinary team of experts including hematologists, oncologists, and human geneticists. It is intended to provide general recommendations in areas where disease-specific recommendations do not yet exist. Here, we describe key issues for the medical care of familial leukemia that shall pave the way for a future consensus guideline: (i) identification of individuals with or suggestive of familial leukemia, (ii) genetic analysis and variant interpretation, (iii) genetic counseling and patient education, and (iv) surveillance and (psychological) support. To address the question on how to proceed with individuals suggestive of or at risk of familial leukemia, we developed an algorithm covering four different, partially linked clinical scenarios, and additionally a decision tree to guide clinicians in their considerations regarding familial leukemia in minors with HM. Our recommendations cover, not only patients but also relatives that both should have access to adequate medical
- Published
- 2023
6. Hypodiploidy has unfavorable impact on survival in pediatric acute myeloid leukemia: An I-BFM Study Group collaboration
- Author
-
Hammer, A. S. B., Juul-Dam, K. L., Sandahl, J. D., Abrahamsson, J., Czogala, M., Delabesse, E., Haltrich, I., Jahnukainen, K., Kolb, E. A., Kovacs, G., Leverger, G., Locatelli, Franco, Masetti, R., Noren-Nystro, U., Raimondi, S. C., Rasche, M., Reinhardt, D., Taki, T., Tomizawa, D., Zeller, B., Hasle, H., Kjeldsen, E., Locatelli F. (ORCID:0000-0002-7976-3654), Hammer, A. S. B., Juul-Dam, K. L., Sandahl, J. D., Abrahamsson, J., Czogala, M., Delabesse, E., Haltrich, I., Jahnukainen, K., Kolb, E. A., Kovacs, G., Leverger, G., Locatelli, Franco, Masetti, R., Noren-Nystro, U., Raimondi, S. C., Rasche, M., Reinhardt, D., Taki, T., Tomizawa, D., Zeller, B., Hasle, H., Kjeldsen, E., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Hypodiploidy, defined as modal numbers (MNs) 45 or lower, has not been independently investigated in pediatric acute myeloid leukemia (AML) but is a well-described high-risk factor in pediatric acute lymphoblastic leukemia. We aimed to characterize and study the prognostic impact of hypodiploidy in pediatric AML. In this retrospective cohort study, we included children below 18 years of age with de novo AML and a hypodiploid karyotype diagnosed from 2000 to 2015 in 14 childhood AML groups from the International Berlin-Frankfurt-Münster (I-BFM) framework. Exclusion criteria comprised constitutional hypodiploidy, monosomy 7, composite karyotype, and t(8;21) with concurring sex chromosome loss. Hypodiploidy occurred in 81 patients (1.3%) with MNs, 45 (n = 66); 44 (n = 10) and 43 (n = 5). The most frequently lost chromosomes were chromosome 9 and sex chromosomes. Five-year event-free survival (EFS) and overall survival (OS) were 34% and 52%, respectively, for the hypodiploid cohort. Children with MN≤44 (n = 15) had inferior EFS (21%) and OS (33%) compared with children with MN = 45 (n = 66; EFS, 37%; OS, 56%). Adjusted hazard ratios (HRs) were 4.9 (P = .001) and 6.1 (P = .003). Monosomal karyotype or monosomy 9 had particular poor OS (43% and 15%, respectively). Allogeneic stem cell transplantation (SCT) in first complete remission (CR1) (n = 18) did not mitigate the unfavorable outcome of hypodiploidy (adjusted HR for OS was 1.5; P = .42). We identified pediatric hypodiploid AML as a rare subgroup with an inferior prognosis even in the patients treated with SCT in CR1.
- Published
- 2023
7. Second allogeneic stem cell transplantation can rescue a significant proportion of patients with JMML relapsing after first allograft
- Author
-
Vinci, L., Flotho, C., Noellke, P., Lebrecht, D., Masetti, R., de Haas, V., De Moerloose, B., Dworzak, M., Hasle, H., Gungor, T., Stary, J., Turkiewicz, D., Ussowicz, M., de Heredia, C. D., Buechner, J., Jahnukainen, K., Kallay, K., Bodova, I., Smith, O. P., Zecca, M., Bresters, D., Lang, P., Masmas, T. N., Meisel, R., Pichler, H., Erlacher, M., Gohring, G., Locatelli, Franco, Strahm, B., Niemeyer, C. M., Yoshimi, A., Locatelli F. (ORCID:0000-0002-7976-3654), Vinci, L., Flotho, C., Noellke, P., Lebrecht, D., Masetti, R., de Haas, V., De Moerloose, B., Dworzak, M., Hasle, H., Gungor, T., Stary, J., Turkiewicz, D., Ussowicz, M., de Heredia, C. D., Buechner, J., Jahnukainen, K., Kallay, K., Bodova, I., Smith, O. P., Zecca, M., Bresters, D., Lang, P., Masmas, T. N., Meisel, R., Pichler, H., Erlacher, M., Gohring, G., Locatelli, Franco, Strahm, B., Niemeyer, C. M., Yoshimi, A., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
NO ABSTRACT
- Published
- 2023
8. Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A -Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group
- Author
-
Van Weelderen, R. E., Klein, K., Harrison, C. J., Jiang, Y., Abrahamsson, J., Arad-Cohen, N., Bart-Delabesse, E., Buldini, B., De Moerloose, B., Dworzak, M. N., Elitzur, S., Fernandez Navarro, J. M., Gerbing, R. B., Goemans, B. F., De Groot-Kruseman, H. A., Guest, E., Ha, S. -Y., Hasle, H., Kelaidi, C., Lapillonne, H., Leverger, G., Locatelli, Franco, Masetti, R., Miyamura, T., Noren-Nystrom, U., Polychronopoulou, S., Rasche, M., Rubnitz, J. E., Stary, J., Tierens, A., Tomizawa, D., Zwaan, C. M., Kaspers, G. J. L., Locatelli F. (ORCID:0000-0002-7976-3654), Van Weelderen, R. E., Klein, K., Harrison, C. J., Jiang, Y., Abrahamsson, J., Arad-Cohen, N., Bart-Delabesse, E., Buldini, B., De Moerloose, B., Dworzak, M. N., Elitzur, S., Fernandez Navarro, J. M., Gerbing, R. B., Goemans, B. F., De Groot-Kruseman, H. A., Guest, E., Ha, S. -Y., Hasle, H., Kelaidi, C., Lapillonne, H., Leverger, G., Locatelli, Franco, Masetti, R., Miyamura, T., Noren-Nystrom, U., Polychronopoulou, S., Rasche, M., Rubnitz, J. E., Stary, J., Tierens, A., Tomizawa, D., Zwaan, C. M., Kaspers, G. J. L., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
PURPOSEA previous study by the International Berlin-Frankfurt-Münster Study Group (I-BFM-SG) on childhood KMT2A-rearranged (KMT2A-r) AML demonstrated the prognostic value of the fusion partner. This I-BFM-SG study investigated the value of flow cytometry-based measurable residual disease (flow-MRD) and evaluated the benefit of allogeneic stem-cell transplantation (allo-SCT) in first complete remission (CR1) in this disease.METHODSA total of 1,130 children with KMT2A-r AML, diagnosed between January 2005 and December 2016, were assigned to high-risk (n = 402; 35.6%) or non-high-risk (n = 728; 64.4%) fusion partner-based groups. Flow-MRD levels at both end of induction 1 (EOI1) and 2 (EOI2) were available for 456 patients and were considered negative (<0.1%) or positive (%0.1%). End points were 5-year event-free survival (EFS), cumulative incidence of relapse (CIR), and overall survival (OS).RESULTSThe high-risk group had inferior EFS (30.3% high risk v 54.0% non-high risk; P <.0001), CIR (59.7% v 35.2%; P <.0001), and OS (49.2% v 70.5%; P <.0001). EOI2 MRD negativity was associated with superior EFS (n = 413; 47.6% MRD negativity v n = 43; 16.3% MRD positivity; P <.0001) and OS (n = 413; 66.0% v n = 43; 27.9%; P <.0001), and showed a trend toward lower CIR (n = 392; 46.1% v n = 26; 65.4%; P =.016). Similar results were obtained for patients with EOI2 MRD negativity within both risk groups, except that within the non-high-risk group, CIR was comparable with that of patients with EOI2 MRD positivity. Allo-SCT in CR1 only reduced CIR (hazard ratio, 0.5 [95% CI, 0.4 to 0.8]; P =.00096) within the high-risk group but did not improve OS. In multivariable analyses, EOI2 MRD positivity and high-risk group were independently associated with inferior EFS, CIR, and OS.CONCLUSIONEOI2 flow-MRD is an independent prognostic factor and should be included as risk stratification factor in childhood KMT2A-r AML. Treatment approaches other than allo-SCT in CR1 are nee
- Published
- 2023
9. P051 - Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: THE EVOLVING GENETIC LANDSCAPE OF PEDIATRIC MDS-EB
- Author
-
Erlacher, M., Yoshimi, A., Stasik, S., Ramamoorthy, S., Lebrecht, D., Noellke, P., Goehring, G., De Haas, V., Starý, J., Masetti, R., Ussowicz, M., Barzilai-Birenboim, S., De Moerloose, B., Kállay, K., Buechner, J., Dworzak, M., Catala, A., Hasle, H., Schmugge, M., Polychronopoulou, S., Boďová, I., Jahnukainen, K., Smith, O., Kavcic, M., Turkiewicz, D., Kjollerstrom, P., Locatelli, F., Wlodarski, M., Thiede, C., Strahm, B., and Niemeyer, C.
- Published
- 2023
- Full Text
- View/download PDF
10. Skeletal adverse events in childhood cancer survivors: An adult life after childhood cancer in Scandinavia cohort study
- Author
-
Oskarsson T, Duun-Henriksen AK, Bautz A, Montgomery S, Harila-Saari A, Petersen C, Niinimaki R, Madanat-Harjuoja L, Tryggvadottir L, Holmqvist AS, Hasle H, Heyman M, and Winther JF
- Subjects
General Economics, Econometrics and Finance - Published
- 2022
11. Temporal changes in the probability of live birth among female survivors of childhood cancer: a population-based adult life after childhood cancer in Scandinavia (ALiCCS) study in five Nordic countries
- Author
-
de, Fine Licht S., primary, Rugbjerg, K., additional, Andersen, E.W., additional, Nielsen, T.T., additional, Nyboe, Norsker F., additional, Kenborg, L., additional, Holmqvist, A.S., additional, Madanat-Harjuoja, L.M., additional, Tryggvadottir, L., additional, Stovall, M., additional, Wesenberg, F., additional, Hjorth, L., additional, Hasle, H., additional, and Winther, J.F., additional
- Published
- 2022
- Full Text
- View/download PDF
12. P09.02.B Engaging Parents in Neuropsychological Rehabilitation for Childhood Cancer Survivors: The I’M aware: Patients And Carers Together (ImPACT) Program
- Author
-
Wu, L M, primary, Henriksen, L T, additional, Buskbjerg, C R, additional, Lassen-Ramshad, Y, additional, Zachariae, R, additional, Evald, L, additional, Hasle, H, additional, and Amidi, A, additional
- Published
- 2022
- Full Text
- View/download PDF
13. PB1938: 4WHIM: EVALUATING MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH WHIM SYNDROME VIA A GLOBAL PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH OPEN-LABEL EXTENSION
- Author
-
Dale, D. C., primary, Alsina, L., additional, Azar, A., additional, Badolato, R., additional, Bertrand, Y., additional, Deya, A., additional, Dickerson, K. E., additional, Ezra, N., additional, Hasle, H., additional, Kang, H. J., additional, Kiani-Alikhan, S., additional, Kuijpers, T., additional, Kulagin, A., additional, Langguth, D., additional, Levin, C., additional, Neth, O., additional, Peake, J., additional, Rutten, C. E., additional, Shcherbina, A., additional, Tarrant, T. K., additional, Vossen, M. G., additional, Wysocki, C. A., additional, Belschner, A., additional, Cadavid, D., additional, Hu, Y., additional, Jiang, H., additional, MacLeod, R., additional, Tang, W., additional, Tillinger, M., additional, and Donadieu, J., additional
- Published
- 2022
- Full Text
- View/download PDF
14. Molecular Measurable Residual Disease Assessment before Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia Patients: A Retrospective Study by the I-BFM Study Group
- Author
-
Benetton, M., Merli, P., Walter, C., Hansen, M., Da Ros, A., Polato, K., Tregnago, C., Abrahamsson, J., Strocchio, L., Sonneveld, E., Fogelstrand, L., Von Neuhoff, N., Reinhardt, D., Hasle, H., Pigazzi, M., Locatelli, Franco, Locatelli F. (ORCID:0000-0002-7976-3654), Benetton, M., Merli, P., Walter, C., Hansen, M., Da Ros, A., Polato, K., Tregnago, C., Abrahamsson, J., Strocchio, L., Sonneveld, E., Fogelstrand, L., Von Neuhoff, N., Reinhardt, D., Hasle, H., Pigazzi, M., Locatelli, Franco, and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Hematopoietic stem cell transplantation (HSCT) is a curative post-remission treatment in patients with acute myeloid leukemia (AML), but relapse after transplant is still a challenging event. In recent year, several studies have investigated the molecular minimal residual disease (qPCR-MRD) as a predictor of relapse, but the lack of standardized protocols, cut-offs, and timepoints, especially in the pediatric setting, has prevented its use in several settings, including before HSCT. Here, we propose the first collaborative retrospective I-BFM-AML study assessing qPCR-MRD values in pretransplant bone marrow samples of 112 patients with a diagnosis of AML harboring t(8;21)(q22; q22)RUNX1::RUNX1T1, or inv(16)(p13q22)CBFB::MYH11, or t(9;11)(p21;q23)KMT2A::MLLT3, or FLT3-ITD genetic markers. We calculated an ROC cut-off of 2.1 × 10−4 that revealed significantly increased OS (83.7% versus 57.1%) and EFS (80.2% versus 52.9%) for those patients with lower qPCR-MRD values. Then, we partitioned patients into three qPCR-MRD groups by combining two different thresholds, 2.1 × 10−4 and one lower cut-off of 1 × 10−2, and stratified patients into low-, intermediate-, and high-risk groups. We found that the 5-year OS (83.7%, 68.6%, and 39.2%, respectively) and relapse-free survival (89.2%, 73.9%, and 67.9%, respectively) were significantly different independent of the genetic lesion, conditioning regimen, donor, and stem cell source. These data support the PCR-based approach playing a clinical relevance in AML transplant management.
- Published
- 2022
15. Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS
- Author
-
Bertrums, E. J. M., Zwaan, C. M., Hasegawa, D., de Haas, V., Reinhardt, D. N., Locatelli, Franco, de Moerloose, B., Dworzak, M., Buijs, A., Smisek, P., Kolenova, A., Pronk, C. J., Klusmann, J. -H., Carbone, A., Ferster, A., Antoniou, E., Meshinchi, S., Raimondi, S. C., Niemeyer, C. M., Hasle, H., van den Heuvel-Eibrink, M. M., Goemans, B. F., Locatelli F. (ORCID:0000-0002-7976-3654), Bertrums, E. J. M., Zwaan, C. M., Hasegawa, D., de Haas, V., Reinhardt, D. N., Locatelli, Franco, de Moerloose, B., Dworzak, M., Buijs, A., Smisek, P., Kolenova, A., Pronk, C. J., Klusmann, J. -H., Carbone, A., Ferster, A., Antoniou, E., Meshinchi, S., Raimondi, S. C., Niemeyer, C. M., Hasle, H., van den Heuvel-Eibrink, M. M., Goemans, B. F., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
no abstract
- Published
- 2022
16. Hippocampal Sparing Radiotherapy in adults with Primary Brain Tumors: A comparative planning and dosimetric study using IMPT, IMRT and 3DCRT
- Author
-
Aka, P, Taylor, R, Hugtenburg, R, Lambert, J, Powell, J, Bevolo, T, Gao, M, Gondi, V, Hartsell, W.H, Bolsi, A, Beer, J, Belosi, M.F, Siewert, D, Lomax, A.J, Weber, D.C, Huang, Y.J, Huang, C.C, Chao, P.J, Liu, C, Shang, H, Ding, X, Wang, Y, Mammar, H, Froelich, Sébastien, Alapetite, Claire, Bolle, Stéphanie, Calugaru, Valentin, Feuvret, Loic, Helfre, Sylvie, Champion, Laurence, Goudjil, Farid, Dendal, Remi, Engelholm, S.A, Munck Af Rosenschold, P, Kristensen, I, Smulders, B, Muhic, A, Alkner, S, Jacob, E, Engelholm, S, Aljabab, S, Lui, A, Wong, T, Liao, J, Laramore, G, Parvathaneni, U, Kharouta, M, Pidikiti, R, Jesseph, F, Smith, M, Dobbins, D, Mattson, D, Choi, S, Mansur, D, Machtay, M, Bhatt, A, Lütgendorf-Caucig, C, Dunavölgyi, R, Georg, P, Perpar, A, Fussl, C, Konstantinovic, R, Ulrike, M, Piero, F, Eugen, H, Vidal, M, Gerard, A, Barnel, C, Maneval, D, Herault, J, Claren, A, Doyen, J, Dendale, R, Toutee, A, Pasquie, I, Goudjil, F, Lumbroso Lerouic, L, Levy, C, Desjardins, L, Cassoux, N, Elisei, G, Pella, A, Calvi, G, Ricotti, R, Tagaste, B, Valvo, F, Ciocca, M, Via, R, Mastella, E, Baroni, G, Saotome, N, Yonai, S, Makishima, H, Hara, Y, Inaniwa, T, Sakama, M, Kanematsu, N, Tsuji, H, Furukawa, T, Shirai, T, Sauerwein, W, Finger, P.T, Gallie, B, Gavrylyuk, Y, Thariat, J, Salleron, J, Maschi, C, Fevrier, E, Caujolle, J.P, Hofverberg, P, Angellier, G, Peyrichon, M.L, Breneman, J, Esslinger, H, Pater, L, Vatner, R, Habrand, J.L, Stefan, D, Lesueur, P, Kao, W, Véla, A, Geffrelot, J, Tessonnier, T, Balosso, J, Mahé, M.A, Lim, P.S, Rompokos, V, Chang, Y.C, Royle, G, Gaze, M, Gains, J, Vennarini, S, Francesco, F, Rombi, B, Amichetti, M, Schwarz, M, Lorentini, S, Mee, T, Burnet, N.G, Crellin, A, Kirkby, N.F, Smith, E, Kirkby, K.J, Roggio, M, Buwenge, M, Melchionda, F, Ammendolia, I, Ronchi, L, Cammelli, S, Morganti, A.G, Youn, S.H, Kim, J.Y, Park, H.J, Shin, S.H, Lee, S.H, Hong, E.K, Czerska, K, Winczura, P, Wejs-Maternik, J, Blukis, A, Antonowicz-Szydlowska, M, Rucinski, A, Olko, P, Badzio, A, Kopec, R, Franceschini, D, Cozzi, L, De Rose, F, Meattini, I, Fogliata, A, Cozzi, S, Becherini, C, Tomatis, S, Livi, L, Scorsetti, M, Garda, A, Fattahi, S, Michel, A, Mutter, R, Yan, E, Park, S, Corbin, K, Giap, H, LAM, W.W, Geng, H, Tang, K.K, Lee, T.Y, Kong, C.W, Yang, B, Chiu, T.L, Cheung, K.Y, Yu, S.K, Ma, M, Gao, X, Zhao, Z, Zhao, B, Mullikin, T, Routman, D, Yu, J, Greco, K, Fagundes, M, Shan, J, Daniels, T, Rule, W, DeWees, T, Hu, Y, Bues, M, Sio, T, Liu, W, chenbin, L, yuehu, P, yuenan, W, Bai, Y, Gao, X.S, Zhao, Z.L, Ma, M.W, Ren, X.Y, Salem, A, Woolf, D, Aznar, M, Azadeh, A, Eccles, C, Charlwood, F, Faivre-Finn, C, Teoh, S, Fiorini, F, George, B, Vallis, K, Van den Heuvel, F, Huang, E.Y, Juang, P.J, Pan, S, Hawkins, M, Clarke, M, Lowe, M, Radhakrishna, G, Schaub, S, Bowen, S, Nyflot, M, Chapman, T, Apisarnthanarax, S, Vitek, P, Kubes, J, Vondracek, V, Vinakurau, S, Zamecnik, L, Vitolo, V, Barcellini, A, Brugnatelli, S, Cobianchi, L, Vanoli, A, Fossati, P, Facoetti, A, Dionigi, P, Orecchia, R, Iannalfi, A, Vischioni, B, Ronchi, S, D’Ippolito, E, Petrucci, R, Yamaguchi, H, Honda, M, Hamada, K, Todate, Y, Seto, I, Suzuki, M, Wada, H, Murakami, M, Yu, Z, Zheng, W, Lien-Chun, L, Zhengshan, H, Qing, Z, Jiade, L, Guoliang, J, Fiore, M.R, D'Ippolito, E, Fukumitsu, N, Hayakawa, T, Yamashita, T, Mima, M, Demizu, Y, Suzuki, T, Soejima, T, Hartsell, W, Collins, S, Casablanca, V, Mihalcik, S, Brennan, E, Van Nispen, A, Corbett, A, Mohammed, N, Lee, P, van Nispen, A, Liang, Y.S, Mein, S, Kopp, B, Choi, K, Haberer, T, Debus, J, Abdollahi, A, Mairani, A, Ogino, H, Iwata, H, Hashimoto, S, Nakajima, K, Hattori, Y, Nomura, K, Shibamoto, Y, Li, P, Wu, S, Deng, L, Zhang, G, Zhang, Q, Fu, S, Yang, Z, Zhang, Y, Sasaki, R, Okimoto, T, Akasaka, H, Miyawaki, D, Yoshida, K, Wang, T, Komatsu, S, Fukumoto, T, Shuang, W, Xin, C, zhengshan, H, Shen, F, Vorobyov, N, Andreev, G, Martynova, N, Lyubinsky, A, Kubasov, A, Chen, J, Ma, N, Lu, Y, Zhao, J, Shahnazi, K, Lu, J, Jiang, G, Mao, J, Walser, M, Bojaxhiu, B, Kawashiro, S, Tran, S, Pica, A, Bachtiary, B, Weber, D, Gaito, S, Abravan, A, Richardson, J, Colaco, R, Saunders, D, Brennan, B, Petersen, I, Ahmed, S, Laack, N, Mizoe, J.E, Iizumi, T, Minohara, S, Kusano, Y, Matsuzaki, Y, Tsuchida, K, Serizawa, I, Yoshida, D, Katoh, H, Sakurai, H, Tujii, H, Kim, T.H, Park, J.W, Bo Hyun, K, Hyunjung, K, Sung Ho, M, Sang Soo, K, Sang Myung, W, Young-Hwan, K, Woo Jin, L, Dae Yong, K, Hong, Z, Wang, Z, Koroulakis, A, Molitoris, J, Kaiser, A, Hanna, N, Jiang, Y, Regine, W, DeCesaris, C.M, Choi, J.I, Carr, S.R, Burrows, W.M, Regine, W.F, Simone, C.B, Aihara, T, Hiratsuka, J, Kamitani, N, Higashino, M, Kawata, R, Kumada, H, Ono, K, Chou, Y.C, Dippolito, E, Bonora, M, Alterio, D, Gandini, S, Jereczeck, B.A, Kelly, C, Dobeson, C, Iqbal, S, Chatterjee, S, Hague, C, Li, T, Lin, A, Lukens, J, Slevin, N, Thomson, D, van Herk, M, West, C, Teo, K, Jeans, E, Manzar, G, Patel, S, Ma, D, Lester, S, Foote, R, Friborg, J, Jensen, K, Hansen, C.R, Andersen, E, Andersen, M, Eriksen, J.G, Johansen, J, Overgaard, J, Grau, C, Dědečková, K, Vítek, P, Ondrová, B, Sláviková, S, Zapletalová, S, Zapletal, R, Vondráček, V, Rotnáglová, E, Kwanghyun, J, Woojin, L, Dongryul, O, Yong Chan, A, Paudel, N, Schmidt, S, Ruckman, M, Gans, S, Stauffer, M, Helenowski, I, Patel, U, Samant, S, Gentile, M, Damico, N, Yao, M, Shuja, M, Routman, D.M, Foote, R.L, Garces, Y.I, Neben-Wittich, M.A, Patel, S.H, McGee, L.A, Harmsen, W.S, Ma, D.J, Sommat, K, Tong, A.K.T, Hu, J, Ong, A.L.K, Wang, F, Sin, S.Y, Wee, T.S, Tan, W.K, Fong, K.W, Soong, Y.L, Wallace, N, Fredericks, S, Fitzgerald, T, Vernimmen, F, Petringa, G, Cirrone, P, Agosteo, S, Attili, A, Cammarata, F.P, Cuttone, G, Conte, V, La Tessa, C, Manti, L, Rosenfeld, A, Lojacono, P.A, Hennings, F, Fattori, G, Peroni, M, Lomax, A, Hrbacek, J, Nguyen, H.G, Bach Cuadra, M, Sznitman, R, Schalenbourg, A, Pflaeger, A, Weber, A, Seidel, S, Stark, R, Heufelder, J, Mailhot Vega, R, Bradley, J, Lockney, N, Macdonald, S, Liang, X, Mazal, A, Mendenhall, N, Sher, D, Korreman, S.S, Andreasen, S, Petersen, J.B, Offersen, B.V, Gergelis, K, Jethwa, K, Whitaker, T, Shiraishi, S, Shumway, D, Press, R, Shelton, J, Zhang, C, Dang, Q, Tian, S, Shu, T, Seldon, C, Jani, A, Zhou, J, McDonald, M, Gort, E, Beukema, J.C, Spijkerman-Bergsma, M.J, Both, S, Langendijk, J.A, Matysiak, W.P, Brouwer, C.L, Baba, K, Numajiri, H, Murofushi, K, Oshiro, Y, Mizumoto, M, Onishi, K, Nonaka, T, Ishikawa, H, Okumura, T, Dominietto, M, Adam, K, Ahlhelm, F.J, Safai, S, Abdul-Jabbar, L, Song, J, Tseng, Y. D, Rockhill, J, Fink, J, Chang, L, Halasz, L. M, Guntrum, F, Steinmeier, T, Nagaraja, S, Jazmati, D, Geismar, D, Timmermann, B, Plaude, S, Lynch, C, Petras, K, Chang, J, Grimm, S, Lukas, R, Kumthekar, P, Merrell, R, Kalapurakal, J, Gross, J, Hoppe, B, Simone, C, Nichols, R.C, Pham, D, Mohindra, P, Chon, B, Morris, C, Li, Z, Flampouri, S, Powell, J.R, Murray, L, Burnet, N, Fernandez, S, Lingard, Z, McParland, L, O’Hara, D, Whitfield, G, Short, S.C, Guan, X, Gao, J, Hu, W, Yang, J, Xing, X, Hu, C, Kong, L, Zou, Z, Thomas, H, Sasidharan, B.K, Rengan, R, Zeng, J, Busold, S, Heese, J, Cerello, P, Bottura, L, Felcini, E, Ferrero, V, Monaco, V, Pennazio, F, de Rijk, G, Chang, H, KyungDon, C, Byunghun, H, Gyuseong, C, Chilukuri, S, Jalali, R, Panda, P.K, Korn, G, Larosa, G, Russo, A, Schillaci, F, Scuderi, V, Margarone, D, Fredén, E, Almhagen, E, Mejaddam, Y, Siegbahn, A, Guardiola, C, Gómez, F, Prieto-Pena, J, Fleta, C, De Marzi, L, Prezado, Y, Kabolizadeh, P, Reitemeier, P, Navin, M, Hamstra, D, Anderson, J, Stevens, C, Bartolucci, L, Adrien, C, Lejars, M, Vaillant, M, Fourquet, A, Robillard, M, Costa, E, Kirova, Y, Kolano, A.M, Degiovanni, A, Farr, J.B, Kundel, S, Pinto, M, Kurichiyanil, N, Würl, M, Englbrecht, F, Hillbrand, M, Schreiber, J, Parodi, K, Kurup, A, Magliari, A, Perez, J, Masui, S, Asano, T, Owen, H, Burt, G, Apsimon, R, Pitman, S, Popovici, M.A, Vasilache, R, Safavi-Naeini, M, Chacon, A, Howell, N, Middleton, R.J, Fraser, B, Guatelli, S, Rendina, L, Matsufuji, N, Gregoire, M.C, Sikora, K, Pettingell, J, Crocker, M, Saplaouras, A, Snijders, A, Mao, J.H, Nakamura, K, Bin, J, Gonsalves, A, Mao, H.S, Steinke, S, Roach, M, Leemans, W, Blakely, E, Takayama, K, Tan, T.S, Wee, J.T.S, Tuan, J.K.L, Wang, M.L.C, Quah, J.S.H, Tay, N.C.W, Lee, J.C.L, Lim, J.K.H, Oei, A.A, Tan, J.M, Park, S.Y, Chow, W.W.L, Omar, Y.B, Chew, P.G, Taylor, P, Lee, J, Tsurudome, T, Hirabayashi, M, Tsutsui, H, Yoshida, J, Takahashi, N, Kamiguchi, N, Hashimoto, A, Tachikawa, T, Mikami, Y, Kumata, Y, Wang, M, Chua, E.T, Wee, J, Wong, F.Y, Tuan, J, Master, Z, Wong, S, Welsh, J, Hentz, C, Pankuch, M, DeJongh, F, Xia, Y, Aitkenhead, A.H, Appleby, R, Merchant, M.J, MacKay, R.I, Young, H, Hughes, V, Alsulimane, M, Barajas, C.A, Taylor, J, Casse, G, Omar, A, Burdin, S, Boon, C, Lester, J, Thomas, A.J, Khan, A, Huthart, L, Leaver, K, Snell, J, Warlow, A, Burigo, L.N, Oborn, B, Belosi, F, Fredh, A, van de Water, S, Schneider, T, Patriarca, A, Bergs, J, Hierso, E, Hirayama, R, Martínez-Rovira, I, Seksek, O, Shirato, H, Nakamura, T, Ogino, T, Akimoto, T, Tamamura, H, Nishimoto, N, Proton-Net, G, Shimizu, S, Fabiano, S, Bangert, M, Guckenberger, M, Unkelbach, J, Mcauley, G, Teran, A, Slater, J, Wroe, A, Boon, I, Clorley, J, Owen, K, Oliver, T, Cicchetti, A, Ballarini, F, Rancati, T, Carrara, M, Zaffaroni, N, Bezawy, R. El, Carante, M, Valdagni, R, Faccini, R, Forte, G.I, Dhinsey, S, Greenshaw, T, Parsons, J, Welsch, C, Stock, M, Grevillot, L, Kragl, G, Carlino, A, Martino, G, Hug, E, Arya, H, Chirayath, V.A, Jin, M, Weiss, A.H, Glass, G.A, Chi, Y, Kaplan, L.P, Perez, R.A, Vestergaard, A, Gittings, E, Stamper, J, Beltran, C, Mark, P, Furutani, K, McAuley, G, Gordon, J, Boisseau, P, Dart, A, Nett, W, Kollipara, S, Grossmann, M, Actis, O, Diete, W, Rudolf, D, Klein, H.U, Kramert, R, Meer, D, Venkataraman, C, Waterstradt, T, Hérault, J, Bergerot, J.M, Hsi, W.C, Zhou, R, Zhang, X, Yang, F, Yinxiangzi, S, Sun, J, Li, X, Zhiling, C, Yuehu, P, Mengya, G, Haiyun, K, Qi, L, Zhentang, Z, Lin, Y.H, Tan, H.Q, Tan, L.K.R, Ang, K.W, Xiufang, L, Milkowski, K, Pang, D, Jones, M, Mizota, M, Tsunashima, Y, Himukai, T, Ogata, R, Uno, T, Ouyang, L, Jia, B, Li, D, Paul, K, Pullia, M, Savazzi, S, Lante, V, Foglio, S, Donetti, M, Falbo, L, Casalegno, L, Rousseau, M, Shinomiya, K, Yazawa, T, Iseki, Y, Kanai, Y, Hirata, Y, Powers, J, Solovev, A, Chernukha, A, Saburov, V, Shegai, P, Ivanov, S, Kaprin, A, Stolarczyk, L, Mojżeszek, N, Van Hoey, O, Farah, J, Domingo, C, Mares, V, Ploc, O, Trinkl, S, Harrison, R, Toltz, A, Nevitt, Z, Bloch, C, Taddei, P, Saini, J, Regmi, R, Yuntao, S, Jinxing, Z, Yap, J.S.L, Hentz, M, Silverman, J, Jolly, S, Boogert, S, Nevay, L, Kacperek, A, Schnuerer, R, Resta-Lopez, J, Zeng, X, Zheng, J, Li, M, Han, M, Song, Y, Holm, A, Korreman, S, Petersen, J.B.B, Bäumer, C, Fuenstes, C, Janson, M, Matic, A, Wulff, J, Psoroulas, S, Lomax, T, Arjomandy, B, Athar, B, Tesfamicael, B, Bejarano Buele, A, Deemer, J, Kozlyuk, V, VanSickle, K, Bolt, R, van Goethem, M.J, Langendijk, J, van t Veld, A, Chen, K.L, Wlodarczyk, B, Wu, H, Chen, Z, Shen, L, Fachouri, N, Placidi, L, Böhlen, T, Ieko, Y, Iwai, T, Nemoto, K, Suzuki, K, Kanai, T, Miyasaka, Y, Harada, M, Yamashita, H, Kubota, I, Kayama, T, Jensen, M.F, Bræmer-Jensen, P, Randers, P, Søndergaard, C.S, Nørrevang, O, Taasti, V.T, Kong, H, Yin, C, Gu, M, Liu, M, Shu, H, Chongxian, Y, Haiyang, Z, Juan, Z, Ming, L, Manzhou, Z., Liying, Z, Kecheng, C, Xiaolei, D, Castro, J, Freire, J, Cremades, M, Moral, L, Rico, P, Ares, C, Miralbell, R, Shi, J, Xia, J, Wang, B, Li, Q, Liu, X, Sung, C.C, Chen, W.P, Liao, T.Y, Takashina, M, Hamatani, N, Tsubouchi, T, Yagi, M, Mizoe, J, Titt, U, Mirkovic, D, Yepes, P, Wang, Q, Grosshans, D, Wieser, H.P, Mohan, R, Vadrucci, M, Xiao, G, Cai, X, Li, G, Yuan, Y, Lu, R, Sun, G, Zhang, M, Deming, L, lianhua, O, Takada, K, Tanaka, S, Matsumoto, Y, Naito, F, Kurihara, T, Nakai, K, Matsumura, A, Sakae, T, Shamurailatpam, D, P, K, Mp, N, A, M, Kg, G, T, R, C, S, J, R, Rozes, A, Dutheil, P, Batalla, A, Vela, A, Rana, S, Bennouna, J, Gutierrez, A, He, P, Shen, G, Dai, Z, Ma, Y, Chen, W, Pandey, J, Chirvase, C, Osborne, M, Ilsley, E, Di Biase, I, Kato, T, Hirose, K, Arai, K, Motoyanagi, T, Harada, T, Takeuchi, A, Kato, R, Tanaka, H, Mitsumoto, T, Takai, Y, Bolsa-Ferruz, M, Palmans, H, Chen, Y.S, Wu, S.W, Huang, H.C, Wang, H.T, Yeh, C.Y, Chen, H.H, Cook, H, Lourenço, A, Dal Bello, R, Magalhaes Martins, P, Hermann, G, Kihm, T, Seimetz, M, Brons, S, Seco, J, De Saint-Hubert, M, Swakon, J, De Freitas Nascimento, L, Tessaro, V.B, Poignant, F, Gervais, B, Beuve, M, Galassi, M.E, Harms, J, Chang, C.W, Zhang, R, Lin, Y, Langen, K, Liu, T, Lin, L, Howard, M, Denbeigh, J, Remmes, N, Debrot, E, Herman, M, Huang, Y.Y, Tsai, S.H, Fang, F.M, Mizuno, H, Sagara, T, Yamazaki, Y, Kato, M, Oyama, S, Pembroke, C, Joslin-Tan, T, Maggs, R, O’Neil, K, Barrett-Lee, P, Staffurth, J, Resch, A, Heyes, P, Georg, D, Fuchs, H, Hideyuki, M, katsuhisa, N, Wataru, Y, Samnøy, A.T, Ytre-Hauge, K.S, Povoli, M, Kok, A, Summanwar, A, Linh, T, Malinen, E, Röhrich, D, Asp, J, Santos, A, Afshar, V.S, Zhang, W.Q, Bezak, E, a, M, k, G, p, K, mp, N, t, R, c, S, j, R, Smith, B, Hammer, C, Hyer, D, DeWerd, L, Culberson, W, Brooke, M, Straticiuc, M, Craciun, L, Matei, C.E, Radu, M, Xiao, M, Paschalis, S, Joshi, P, Price, T, Mehta, M, Graça, J, Biglin, E, Aitkenhead, A, Price, G, Williams, K, Chadwick, A, Schettino, G, Robinson, A, Kirkby, K, Catanzano, D, Cessac, R, Rutherford, R, Ahmed, A, Mohammadi, A, Tashima, H, Yamaya, T, Chavez Barajas, C, Taylor, A, Vossebeld, J, Barwick, I, CHEON, W, Jo, K, Ahn, S.W, Cho, J, Han, Y, Choi, H.H.F, Cheung, C.W, Cohilis, M, Lee, J.A, Sterpin, E, Souris, K, Mundy, D, Petasecca, M, Rosenfeld, A.B, Boso, A, Di Fulvio, A, Becchetti, F.D, Torres-Isea, R.O, Febbraro, M, Gagnon-Moisan, F, Feng, Y, Fontana, M, Etxebeste, A, Dauvergne, D, Letang, J.M, Testa, E, Sarrut, D, Maxim, V, Gajewski, J, Durante, M, Garbacz, M, Krah, N, Krzempek, K, Schiavi, A, Skrzypek, A, Tommasino, F, Ruciński, A, Gillin, M, Sahoo, N, Zhu, X.R, Van Delinder, K.W, Crawford, D, Khan, R, Gräfe, J, Kakiuchi, G, Shioyama, Y, Shimokomaki, R, Huang, Z, Wang, W, Sheng, Y, Lee, M.W, Jan, M.L, Hong, J.H, Okamoto, K, Sato, H, Kalantan, S, Boston, A, Kang, Y, Shen, J, Casey, W, Vern-Gross, T, Wong, W, McGee, L, Halyard, M, Keole, S, Kelleter, L, Radogna, R, Saakyan, R, Basharina-Freshville, A, Attree, D, Volz, L, Komenda, W, Krzempek, D, Mierzwińska, G, Barbara, M, Kopeć, R, Lan, J.H, Chang, F.X, Lin, C.H, Lee, T.F, Ahn, S, Cheon, W, Lee, M, Letellier, V, Osorio, J, Dreindl, R, Livingstone, J, Gallin-Martel, M.L, Létang, J.M, Marcatili, S, Morel, C, Maggi, P, Chen, H, Yang, H, Panthi, R, Mackin, D, Peterson, S, Beddar, S, Polf, J, Masuda, T, Nishio, T, Sano, A, Tomozawa, H, Nishio, A, Tsuneda, M, Okamoto, T, Karasawa, K, Miszczynska Giza, O, Sánchez-Parcerisa, D, Herraiz, J. L, Rojo-Santiago, J, Udias, J.M, Mitrović, U, Hager, M, List, I, Fischer, C, Cecowski, M, Gajšek, R, Mizutani, S, Hotta, K, Baba, H, Tanizaki, N, Yamaguchi, T, Moon, S.Y, Rah, J.E, Yoon, M, Shin, D, Nebah, P, Dugas, J, Syh, J, Maynard, M, Marsh, N, Rosen, L, Nichiporov, D, Watts, D.A, Chen, Y, Petterson, M, Lee, W.D, Penfold, S.N, Ruebel, N, Piersimoni, P, Mille, M, Mossahebi, S, Chen-Mayer, H, Allport, P, Green, S, Shaikh, S, Walker, D, Qamhiyeh, S, Levegruen, S, Kutscher, S, Kranke, H, Olbrich, G, Stuschke, M, Baran, J, Pawlik-Niedzwiecka, M, Moskal, P, Rutherford, H, Poenisch, F, Martin, C, Wu, R, Mayo, L.L, Shah, S.J, Frank, S.J, Gunn, G.B, Sakurai, Y, Takata, T, Kondo, N, Schlegel, N, Deng, Y, Sun, W, Wu, X, Yap, J, Zhang, H, Szumlak, T, Schuy, C, Simeonov, Y, Zink, K, Graeff, C, Weber, U, Allred, B, Robertson, D, Dewees, T, Gagneur, J, Stoker, J, Stützer, K, Valentini, C, Agolli, L, Hölscher, T, Thiele, J, Dutz, A, Löck, S, Krause, M, Baumann, M, Richter, C, Takayanagi, T, Uesaka, T, Nakamura, Y, Unlu, M.B, Kuriyama, Y, Uesugi, T, Ishi, Y, Umegaki, K, Matsuura, T, Watts, D. A, Huisman, B, Valladolid Onecha, V, Fraile, L.M, Sanchez Parcerisa, D, España, S, Ze, W, Chen, H.Y, Chuang, K.S, Wilson, M, Lui, J, Noble, D, Holloway, S, Yap, J.H.H, Chew, M.M.L, Pang, P.P, Lim, C.J.C, Gan, S.A, Tan, T.W.K, Shen, Z.M, Moyers, M, Qianxia, W, Chen, H.L, Li, J, Lin, J, Zhao, L, Myers, W, Ates, O, Faught, J, Yan, Y, Faught, A, Sobczak, D, Hua, C.H, Moskvin, V, Merchant, T, Henkner, K, Ecker, S, Chaudhri, N, Ellerbrock, M, Jäkel, O, Hernandez Morales, D, Augustine, K, Johnson, J, Younkin, J, Fiorina, E, Mattei, I, Morrocchi, M, Sarti, A, Traini, G, Valle, S.M, Bert, C, Karger, C.P, Kamada, T, Scholz, M, DeLuca, P.M, De Simoni, M, Dong, Y, Embriaco, A, Fischetti, M, Mancini-Terracciano, C, Mirabelli, R, Muraro, S, Lens, E, de Blécourt, A, Schaart, D, Vos, F, van Dongen, K, Berthold, J, Khamfongkhruea, C, Petzoldt, J, Wohlfahrt, P, Pausch, G, Janssens, G, Smeets, J, Shamblin, J, Blakey, M, Moore, R, Matteo, J, Schreuder, N, Derenchuk, V, Shin, J, Jee, K.W, Clasie, B.M, Depauw, N, Batin, E, Madden, T.M, Schuemann, J, Paganetti, H, Kooy, H.M, Daniel, M, Abbassi, L, Arsène-Henry, A, Amessis, M, Maes, S, O’Ryan-Blair, A, Laval, G, Ermoian, R, Taddei, P. J, Andersson, K, Norrlid, O, Lindbäck, E, Vallhagen Dahlgren, C, Witt Nyström, P, Argota Perez, R, Sharma, M.B, Elstrøm, U.V, Bizzocchi, N, Albertini, F, Branco, D, Kry, S, Rong, J, Frank, S, Followill, D, Busch, K, Muren, L.P, Thörnqvist, S, Andersen, A.G, Pedersen, J, Dong, L, Cao, W, Bai, X, Van Lobenstein, N, Traneus, E, Anson, C, Comi, S, Marvaso, G, Russo, S, Giandini, T, Avuzzi, B, Ciardo, D, Cattani, F, Jereczek-Fossa, B, Cotterill, J, Esposito, M, Winter, A, Allinson, N, Liu, G, Yan, D, Jawad, S, Dilworth, J, Chen, P, Ackermann, B, Florijn, M, Sharfo, A.W.M, Wiggenraad, R.G.J, van Santvoort, J.P.C, Petoukhova, A.L, Hoogeman, M.S, Mast, M.E, Dirkx, M.L.P, Fujitaka, S, Fujii, Y, Nihongi, H, Nakayama, S, Ho, M.W, Artz, M, Tong, K.T.A, Hytonen, R, Koponen, T, Niemela, P, Iancu, G, Lautenschlaeger, S, Eberle, F, Horst, F, Ringbaek, T, Engenhart-Cabillic, R, Kim, M.J, Hong, C.S, Kim, Y.B, Park, S.H, Kim, J.S, Reiterer, J, Steffal, C, Gora, J, Kann, T, Schratter-Sehn, A.U, Li, H, Chen, M, wu, R, Li, Y, zhang, X, Gautam, A, poenisch, F, sahoo, N, Zhu, R, Lin, M, Chang, J.T.C, Maeda, Y, Sato, Y, Shibata, S, Bou, S, Yamamoto, K, Sasaki, M, Fuwa, N, Takamatsu, S, Kume, K, Lim, F, Faller, F, Stiller, W, Ming, X, Hui, H, Mukawa, T, Takashi, Y, Stephenson, L, Pang, E.P.P, Paz, A.E, Yoshida, Y, Righetto, R, Vecchi, C, Alparone, A, De Spirito, M, Radhakrishnan, S, Chandrashekaran, A, Nandigam, J, Sarma, Y, Rechner, L, Munck af Rosenschöld, P, Bäck, A, Johansen, T.S, Schut, D.A, Aznar, M.C, Nyman, J, Ren, X, Rosas, S, Vanderstraeten, R, Jyske, T, Jari, L, Yuenan, W, Henthorn, N, Warmenhoven, J, Merchant, M, Kirkby, N, Ranald, M, Stefanowicz, S, Zschaeck, S, Troost, E.G.C, Stubington, E, Ehrgott, M, Nohadani, O, Shentall, G, Sun, T, yin, Y, Lin, X, Yoshimura, T, Matsuo, Y, Yamazaki, R, Takao, S, Miyamoto, N, Toussaint, L, Indelicato, D.J, Lassen-Ramshad, Y, Kirby, K, Mikkelsen, R, Di Pinto, M, Høyer, M, Stokkevåg, C.H, Van Herk, M, Shortall, J, Green, A, Vasquez Osorio, E, Mackay, R, Navratil, M, Andrlik, M, Chiang, Y.Y, Yeh, Y.H, Yeh, Y.J, Chang, T.C, Eaton, B, Yang, X, Esiashvili, N, Gu, W, Ruan, D, O’Connor, D, Zou, W, Tsai, M.Y, Jia, X, Sheng, K, Hyde, C, Chen, P.Y, Deraniyagala, R, Petoukhova, A, Klaassen, L, Habraken, S, Jacobs, J, Sattler, M, Verhoeven, K, Klaver, Y, Widesott, L, Fracchiolla, F, Algranati, C, Scifoni, E, Scartoni, D, Farace, P, Kröniger, K, Bauer, J, Nilsson, R, Chen, X, Liu, R, Sun, B, Mutic, S, Zhang, T, Zhao, T, Kajdrowicz, T, Wochnik, A, Swakoń, J, Małecki, K, Michalec, B, Moffitt, G, Wootton, L, Hardemark, B, Sandison, G, Emery, R, Stewart, R, Reidel, C.A, Finck, C, Deisher, A, Mahajan, A, Michael, H, Ahn, S.H, Kwang Hyeon, K, Chankyu, K, Youngmoon, G, Shinhaeng, C, Se Byeong, L, Young Kyung, L, Haksoo, K, Dongho, S, Jong Hwi, J, Ali, Y, Monini, C, Maigne, L, Alshaikhi, J, D’Souza, D, Amos, R. A, Baumann, K.S, Gomà, C, Flatten, V, Lautenschläger, S, Abdel-Rehim, A, Wan Chan Tseung, H.S, Ma, J, Kamal Syed, H, Boscolo, D, Krämer, M, Fuss, M, Braunroth, T, Rabus, H, Baek, W.Y, Brown, H, Alshammari, H, Brownstein, J, Giantsoudi, D, Wang, C.C, Grassberger, C, Chen, C, Chan, M.F, Mah, D, Hojo, Y, Xu, C, Elia, A, Fung, A, Nguyen, B.N, Oyervides, M, Koska, B, Kamal Sayed, H, Kim, C, Kim, Y.J, Lee, S.B, Goh, Y, Cho, S, Jeong, J.H, Kim, H, Lim, Y.K, Koh, W.Y.C, Lew, W.S, Lee, C.L.J, Kollitz, E, Han, H, Kim, C.H, Kroll, C, Riboldi, M, Newhauser, W, Dedes, G, Fuglsang Jensen, M, Nyström, U.H, Skyt, P.S, Hoffmann, L, Sloth Møller, D, Dokic, I, Kuo, S.H, Tai, P.L, Cheng, S.W, Chong, N.S, Yeom, Y.S, Kuzmin, G, Griffin, K, Langner, U, Jung, J.W, Lee, C, Lee, C.C, Hsu, W, Chao, T.C, Liamsuwan, T, Pischom, N, Tangboonduangjit, P, Suchada, T, Zheng, D, Rutenberg, M, Dhabaan, A, Harrabi, S, MARAFINI, M, Gioscio, E, Yunsheng, D, Alphonse, G, Rodriguez Lafrasse, C, Testa, É, Morris, B, Asavaphatiboon, S, DeBlois, D, Yam, M, Sękowski, P, Skwira-Chalot, I, Matulewicz, T, Flynn, R, Verbeek, N, Smyczek, S, Brualla, L, Lei, Y, Ghavidel, B, Curran, W, Beitler, J, Yu, H.W, Jeng, S.C, Tsai, Y.C, Chiou, J.F, Yusa, K, Dai, T, Yuan, P, Shafai-Erfani, G, Shu, H.K, Pepin, M, Tryggestad, E.J, Abdel Rehim, A, Johnson, J.E, Herman, M.G, Lee, S.C, Sheu, R.J, Ödén, J, Ramos-Mendez, J, Perl, J, Faddegon, B, Alaka, B.G, Bentefour, E.H, Samuel, D, Biradar, B, Frusti, P, Den Otter, L.A, Kurz, C, Stanislawski, M, Landry, G, Meijers, A, Knopf, A.C, Dickmann, J, Wesp, P, Rit, S, Johnson, R.P, Bashkirov, V, Schulte, R.W, Hoyle, B, Johnson, R, Schulte, R, Weller, J, Cotterill, J.V, Waltham, C, Allport, P.P, Taylor, M, Rogers, J, Evans, P.M, Allinson, N.M, Henry, T, Ardenfors, O, Gudowska, I, Poludniowski, G, Dasu, A, Lai, Y, Yuncheng, Z, Yiping, S, Mingwu, J, Xun, J, Yujie, C, Meric, I, Mattingly, J, Moustafa, A, Skjerdal, K, Moteabbed, M, Harisinghani, M, Efstathiou, J.A, Lu, H.M, Kabuki, S, Mizowaki, T, Ofierzynski, R, Paysan, P, Strzelecki, A, Lucca, R, Patch, S, Mustapha, B, Santiago-Gonzalez, D, Pettersen, H.E.S, Sølie, J, Levegrün, S, Pöttgen, C, Meyer, E, Collins-Fekete, C.A, Bashkirov, V.A, Wang, Y.M, Sung, K.C, Wang, C.J, Wu, H.Y, Winter, M, Bauer, U, Hansmann, T, Naumann, J, Peters, A, Pilz, K, Troost, E, Yan, S, Greenhalgh, J, Li, S, Bortfeld, T, Flanz, J, Ytre-Hauge, K, Zhang, L, Sharp, G.C, Cascio, E.W, Flanz, J.B, Tang, J, Zhu, J, Zhang, J, Uh, J, Sarosiek, C, Ricci, J, Coutrakon, G, Ozoemelam, I, van der Graaf, E.R, Maciej, K, Zhang, N, Brandenburg, S, Dendooven, P, Niepel, K, Yohannes, I, Dietrich, O, Ertl-Wagner, B, Pappas, E, Sølie, J.R, Odland, O.H, Ghesquiere-Dierickx, L.M.H, Felix Bautista, R, Gehrke, T, Jakubek, J, Turecek, D, Martisikova, M, Malekzadeh, E, Rajabi, H, Kalantari Mahmoudabadi, F, Meschini, G, d’Arenzo, D, Comini, D, Huynh, M.T, Paganelli, C, Fontana, G, Mancin, A, Preda, L, Su, Z, Henderson, R, Nichols, C, Bryant, C, Mendenhall, W, Boyer, B, Geerebaert, Y, Gevin, O, Koumeir, C, Magniette, F, Manigot, P, Poirier, F, Servagent, N, Thiebaux, C, Verderi, M, Chen, Y.R, Anderle, K, Jeraj, R, Chuter, R, Allan, I, Patel, I, MacKay, R, Harrison, K, Hoole, A, Thomas, S, Jena, R, Liao, Z, Zhu, R.X, Freeman, M, Espy, M, Aulwes, E, Magnelind, P, Merrill, F, Neukirch, L, Sidebottom, R, Tang, Z, Tupa, D, Wilde, C, Shusharina, N, Fullerton, B, Adams, J, Sharp, G, Chan, A, Dolde, K, Naumann, P, Dávid, C, Kachelrieß, M, Saito, N, Pfaffenberger, A, Wolf, M, Lis, M, Moreau, J, Buttion, M, Molitoris, J.K, Simone-, C.B, Regele, H, Bula, C, Danuser, S, Kang, M, Lin, H, Ribeiro, C. O, Dumont, D, Terpstra, J, Knopf, A, Wagenaar, D, Kierkels, R, van der Schaaf, A, Scandurra, D, Sijtsema, M, Korevaar, E, van den Hoek, A, O’Neil, M, Chung, H, Sala, I, Ramirez, H, Guerrero, T, Mondlane, G, Butkus, M.B, Stewart, R.D, Carlson, D.J, Ingram, S, Ytre-Hauge, K. Smeland, Rørvik, E, Perales, A, Carabe, A, Baratto-Roldan, A, Kimstrand, P, Cortes-Giraldo, M, Bertolet, A, Barato-Roldan, A, Baiocco, G, Barbieri, S, Mei, Z, Fan, K, Tang, K, Wang, J, Zhu, H, Sung, W, McNamara, A, Tran, L.T, Qi, Y, Xu, X, Pei, X, Chiang, Y, Chien-Hau, C, Chung-Chi, L, Chuan-Jong, T, Tsi-Chian, C, Wang, L, Cao, J, Wang, X, Lin, E, Minami, K, Kondo, R, Khoei, S, Shirvalilou, S, Khoee, S, Jamali Raoufi, N, Karimi, M.R, Shakeri-Zadeh, A, Patera, V, Rinaldi, I, Sas-Korczynska, B, Deng, W, Karagounis, I, Huynh, K, Maity, A, Abel, E, Santa Cruz, G, Monti Hughes, A, Herrera, M, Trivillin, V, Portu, A, Garabalino, M, Schwint, A, Gonzalez, S, Saint Martin, G, Santa Cruz, I, Tamari, Y, Watanabe, T, Masunaga, S.I, Wittig, A, Nigg, D, Stecher-Rasmussen, F, Moss, R, Igawa, K, Akita, K, Akabori, K, Hattori, K.J, Arima, H, Motoyama, K, Higashi, T, Trivillin, V.A, Pozzi, E.C.C, Thorp1, S.I, Curotto1, P, Garabalino1, M.A, Itoiz, M.E, Santa Cruz, I.S, Ramos, P.S, Palmieri, M.A, Schwint, A.E, Gadan, M.A, Thorp, S.I, Curotto, P, Portu, A.M, Thorp, S, Trivillin, V. A, Schwint, A. E, Fukuo, Y, Kanemitsu, T, Fukumura, M, Kosaka, T, Hiramatsu, R, Kuroiwa, T, Miyatake, S, Kawabata, S, Kirihata, M, Goldfinger, J.A, Garabalino, M.A, Pozzi, E.C, Ramos, P, De Leo, L.N, Yu, Q, Engelbrecht, M, Sioen, S, Miles, X, Nair, S, Ndimba, R, Baeyens, A, Vandevoorde, C, Buizza, G, Meng, J, Takai, N, Ogami, M, Nakamura, S, Ohba, Y, Liu, R.F, Zhang, Q.N, Wang, X.H, Luo, H.T, Kong, Y.R, Jansen, J, Tirinato, L, Marafioti, M.G, Hanley, R, Yao, X.Q, Pagliari, F, Huang, C.Y, Wong, W.K.R, Ho, Y.W, Nam, P.H, Koryakin, S.N, Troshina, M.V, Koryakina, E.V, Potetnya, V.I, Baykuzina, R.M, Lychagin, A.A, Ulyanenko, S.E, Molinelli, S, Giuseppe, M, Tran, L, Bolst, D, James, B, Steinsberger, T, Alliger, C, Dahle, T.J, Rusten, E, Wright, P, Forsback, S, Silvoniemi, A, Minn, H, Andersson, S, Buti, G, Barragán Montero, A.M, Vasquez-Osario, E, Sabouri, P, Nkenge, K, Yi, B, Burigo, L, Greilich, S, Thomas, R, Clark, C, Lourenco, A, Oancea, C, Granja, C, Kodaira, S, Coplan, M, Graybill, J, Lutz, L, Shahi, C, Su, J.J, Thompson, A, Romano, F, Shipley, D, Hong, T.S, Labarbe, R, Wolfgang, J.A, Meyer, S, Bortfeldt, J, Lämmer, P, Schnürle, K, Peters, N, Möhler, C, Hofmann, C, Koschik, A, Bryce-Atkinson, A, Van Nugteren, J, De Rijk, G, Kirby, G, Dutoit, B, Vignati, A, Ahmadi Ganjeh, Z, Fausti, F, Giordanengo, S, Hammad Ali, O, Sacchi, R, Shakarami, Z, Cirio, R, Inoue, J, Tachibana, M, Shimizu, Y, Ochi, T, Amano, D, Miyashita, T, Cooley, J, Nyamane, S, Zwart, T, Wagner, M, Lu, M, Rosenthal, S, Hashimoto, T, Katoh, N, Tamura, H, Emert, F, Missimer, J, Eichenberger, P, Gmuer, C, Spengler, C, Kamp, F, Hofmaier, J, Reiner, M, Belka, C, Van Ooteghem, G, Dasnoy-Sumell, D, Geets, X, Chen, C.C, Galbreath, G, Shmulenson, R, Pinheiro de Almeida, I, van Elmpt, W, Vilches Freixas, G, Unipan, M, Verhaegen, F, Bosmans, G, Garcia, G, Cevallos Robalino, L, Guzman-Garcia, K, Vega-Carrillo, H.R, Gomez-Ros, J.M, Gallego, E, Hintenlang, K, Martin, M, Gupta, N, Meissner, J, Smathers, J, Ainsley, C, Yin, L, Jagt, T, Breedveld, S, van Haveren, R, Nout, R, Astreinidou, E, Staring, M, Heijmen, B, Hoogeman, M, Stokes, W, Matter, M, Nenoff, L, Toramatsu, C, Wakizaka, H, Nitta, M, Nishikido, F, Hirano, Y, Yoshida, E, Miller, J, Maris, A, Kalle, R, Franco, G, Kierkels, R.G.J, van den Hoek, J.G.M, Bijl, H.P, Dieters, M, Steenbakkers, R.J.H.M, Dejongh, F, DeJongh, E, Rykalin, V, Karonis, N, Ordonez, C, Duffin, K, Winans, J, Neph, R, Sanchez-Parcerisa, D, Lopez-Aguirre, M, Dolcet Llerena, A, Udias, J, Oxley, D, Besson, R, Meier, G, Nanz, A, Schorta, M, Fleury, E, Trnková, P, Erdal, E, Hassan, K, Beenakker, J.W, Pignol, J.P, Matysiak, W, Tian, L, Zepter, S, Winterhalter, C, Shim, S, Gouldstone, C, Trnkova, P, Vatnitsky, S, Liu, K, Li, E, Zhuangming, S, Lowenstein, J, De Wilde, O, Bossier, V, Lerot, X, Pouppez, A, Xx, X, Verburg, J, Hueso-Gonzalez, F, Ruggieri, T, Amato, C, Ghesquiere-Dierickx, L, Felix-Bautista, R, Deville, C, Barsky, A, Vapiwala, N, Mohamad, O, Tabuchi, T, Nitta, Y, Nomoto, A, Kasuya, G, Choy, H, Miyashiro, I, Bush, D, Chuong, M, Kozarek, J, Rubens, M, Larson, G, Vargas, C, Hung, S.P, Hsieh, C.E, Huang, B.S, Tsang, N.M, Smith, N, Viehman, J, Harmsen, W, Elswick, S, Boughey, J, Harless, C, Jimenez, R, Hickey, S, DePauw, N, Ho, A, Taghian, A, MacDonald, S, Meek, A, Hedrick, S, Baliga, S, Gallotto, S, Lewy, J, Patteson, B, Speroni, S, Omsberg, A, Tarbell, N, Musolino, P, Yock, T, Indelicato, D, Rotondo, R, Mailhot, R, Uezono, H, Bradfield, S, Agarwal, V, Gillies, C, Gosling, A, Casares-Magaz, O, Eskildsen, S.F, Lassen, Y, Hasle, H, Tofting-Olesen, K, Alapetite, C, Puget, S, Nauraye, C, Beccaria, K, Bolle, S, Doz, F, Sainte-Rose, C, Bouffet, E, Zerah, M, Wu, J, Qiu, X, Hua, W, Mao, Y, Frakulli, R, Kramer, P.H, Glas, M, Blase, C, Tippelt, S, Konrath, L, Gruber, N, Schallerbauer-Peter, A, Mock, U, Niyazi, M, Niemierko, A, Schapira, E, Kim, V, Oh, K.S, Hwang, W.L, Busse, P.M, Loeffler, J.S, Shih, H.A, Appel, H, Tseng, Y.D, Tsai, H, Sinesi, C, Rossi, C, Badiyan, S, Kotecha, R, Pike, L, Horick, N, Yeap, B, Franck, K, Wang, I, Loeffler, J, McKenna, M, Shih, H, Kountouri, M, Kole, A.J, Murray, F.R, Kliebsch, U, Combescure, C, iannalfi, A, Riva, G, Dougherty, J, Kruse, J, Iott, M, Brown, P, Olivier, K, Brodin, P, Kabarriti, R, Schechter, C, Kalnicki, S, Garg, M, Tomé, W, Lu, J.J, Chen, P.J, Dhanireddy, B, Severo, C, Lee, C.H, Lin, C.R, Rosier, L, Mathis, T, DeLaney, T, Lin, S, O’Meara, E, Powell, T, Hong, T, Hall, D, Liu, A, Ntentas, G, Dedeckova, K, Darby, S, Cutter, D, Zapletalova, S, Chen, Y.L, Miao, R, Lee, H, Hsiao-Ming, L, Choy, E, Cote, G, Eulitz, J, Lutz, B, Enghardt, W, Lühr, A, Mcmahon, S, Prise, K, Sung Hyun, L, Tansho, R, Mizushima, K, Warmenhoven, J.W, Hufnagl, A, Friedrich, T, Deycmar, S, Gruber, S, Dörr, W, Pruschy, M, Waissi, W, Burckel, H, Nicol, A, Noel, G, Yousef, I, Koizumi, M, Santa Cruz, G.A, González, S.J, Longhino, J, Provenzano, L, Oña, P, Rao, M, Cantarelli, M.D.L.Á, Leiras, A, Olivera, M.S, Alessandrini, P, Brollo, F, Boggio, E, Costa, H, Ventimiglia, R, Binia, S, Nievas, S.I, Langle, Y, Eijan, A.M, Colombo, L.L, Kawai, K, Nakamura, H, Natsuko, K, Masaki, H, Nakada, M, Furuse, M, Miyatake, S.I, Koivunoro, H, Kankaanranta, L, González, S, Joensuu, H, Sokol, O, Hild, S, Wiedemann, J, Köthe, A, Perry, D, Batie, M, Mascia, A, Sertorio, M, Luhr, A, Suckert, T, Müller, J, Beyreuther, E, Gotz, M, Haase, R, Schürer, M, Tillner, F, von Neubeck, C, Davis, A, Sishc, B, Saha, J, Ding, L, Story, M, Wagner, S, Kim, S.Y, Geary, S, Woodruff, T, Xu, T, Meng, Q, Gilchrist, S, Perentesis, J.P, Zheng, Y, Wells, S.I, Kong, Y, Liu, Y, Geng, Y, Knoll, M, Schwager, C, Schlegel, J, Schnölzer, M, Ding, L.H, Aroumougame, A, Chen, B, Saha, D, Pompos, A, Carter, R, Nickson, C, Thomson, J, Hill, M, Rodrigues, D, Snider, J, Sharma, A, Zakhary, M, Kara, L, Vujaskovic, Z, Dykstra, M, Best, T, Keane, F, Khandekar, M, Fintelmann, F, Willers, H, Singh, P, Eley, J, Malyapa, R, Mahmood, J, Hårdemark, B, Sandison, G.A, Wootton, L.S, Miyoaka, R.S, Laramore, G.E, Yang, P, van der Weide, H, Maduro, J, Heesters, M, Gawryszuk, A, Davila-Fajardo, R, Langendijk, H, Eckhard, M, Maxwell, A, VanNamen, K, Cashin, M, Jacovic, A, Dunn, M, kim, T, Jung, J, Kim, J, Swerdloff, S, Saunders, A, Thomas, J, Kidani, T, Okada, A, Tomida, K, Pennington, H, Xiaoqiang, L, Weigang, H, An, Q, Di, Y, Craig, S, Inga, G, Peyman, K, Xuanfeng, D, Cunningham, C, de Kock, M, Slabbert, J, Panaino, C.M, Phoenix, B, Regan, P.H, Shearman, R, Collins, S.M, Taylor, M.J, Grayson, M, Kato, K, Choi, H, Jang, J.W, Shin, W.G, Min, C.H, McMahon, S, Padilla Cabal, F, Fragoso, J.A, Resch, A.F, Katsis, A, Girdhani, S, Marshall, A, Jackson, I, Bentzen, S, Parry, R, Gantz, S, Schellhammer, S, Hoffmann, A, Delorme, R, Dos Santos, M, Salmon, R, Öden, J, Bullivant, K, Rucksdashal, R, Ferret, E, Covington, F, Rice, S, Decesaris, C, Siddiqui, O, Kowalski, E, Samanta, S, and Rothwell, B
- Subjects
Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0642 ,Physics: Absolute and Relative DosimetryPTC58-0180 ,Biology: Biology and Clinical InterfacePTC58-0685 ,Physics: Commissioning New FacilitiesPTC58-0385 ,Physics: 4D Treatment and DeliveryPTC58-0546 ,Clinics: EyePTC58-0714 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0528 ,Physics: Quality Assurance and VerificationPTC58-0507 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0661 ,Biology: Translational and Biomarkers Poster Discussion SessionsPTC58-0221 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0531 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0653 ,Biology: Drug and Immunotherapy CombinationsPTC58-0163 ,Clinics: Sarcoma - LymphomaPTC58-0055 ,Biology: Drug and Immunotherapy CombinationsPTC58-0166 ,Clinics: CNS / Skull BasePTC58-0198 ,Physics: Treatment PlanningPTC58-0421 ,Clinics: PediatricsPTC58-0560 ,General: New HorizonsPTC58-0709 ,Physics: Treatment PlanningPTC58-0664 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0286 ,Physics: Treatment PlanningPTC58-0666 ,Biology: Translational and Biomarkers Poster Discussion SessionsPTC58-0346 ,Physics: Treatment PlanningPTC58-0547 ,Physics: Treatment PlanningPTC58-0308 ,Physics: Treatment PlanningPTC58-0549 ,Physics: Beam Delivery and Nozzle Design Poster Discussion SessionsPTC58-0111 ,Physics: Absolute and Relative DosimetryPTC58-0050 ,Biology: Enhanced Biology in Treatment Planning Poster Discussion SessionsPTC58-0587 ,Biology: Biology and Clinical InterfacePTC58-0454 ,Physics: Absolute and Relative DosimetryPTC58-0052 ,Physics: Commissioning New FacilitiesPTC58-0395 ,Physics: 4D Treatment and DeliveryPTC58-0534 ,Physics: Dose Calculation and OptimisationPTC58-0072 ,Physics: 4D Treatment and DeliveryPTC58-0533 ,Physics: 4D Treatment and DeliveryPTC58-0538 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0113 ,Physics: Quality Assurance and VerificationPTC58-0633 ,Physics: Treatment PlanningPTC58-0431 ,Physics: Beam Delivery and Nozzle DesignPTC58-0230 ,Biology: Mathematical Modelling SimulationPTC58-0179 ,Clinics: Head and Neck / EyePTC58-0365 ,Physics: Treatment PlanningPTC58-0319 ,Biology: Translational and Biomarkers Poster Discussion SessionsPTC58-0697 ,Biology: Biology and Clinical InterfacePTC58-0663 ,Physics: Commissioning New FacilitiesPTC58-0240 ,Physics: Adaptive TherapyPTC58-0177 ,Physics: Commissioning New FacilitiesPTC58-0363 ,Physics: Commissioning New FacilitiesPTC58-0487 ,Physics: 4D Treatment and DeliveryPTC58-0209 ,Physics: 4D Treatment and DeliveryPTC58-0206 ,Clinics: CNS / Skull BasePTC58-0294 ,Physics: Commissioning New FacilitiesPTC58-0127 ,Biology: Mathematical Modelling SimulationPTC58-0068 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0062 ,Physics: 4D Treatment and DeliveryPTC58-0692 ,Physics: Quality Assurance and VerificationPTC58-0723 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0494 ,Physics: Treatment PlanningPTC58-0643 ,Physics: Treatment PlanningPTC58-0521 ,Physics: Treatment PlanningPTC58-0402 ,Physics: Treatment PlanningPTC58-0405 ,Clinics: Head and Neck / EyePTC58-0273 ,Clinics: GIPTC58-0397 ,Physics: Treatment PlanningPTC58-0648 ,Biology: Enhanced Biology in Treatment Planning Poster Discussion SessionsPTC58-0489 ,Physics: Quality Assurance and VerificationPTC58-0617 ,Physics: Quality Assurance and VerificationPTC58-0616 ,Physics: Dose Calculation and Optimisation Poster Discussion SessionsPTC58-0668 ,Clinics: CNS / Skull BasePTC58-0188 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0625 ,Physics: Treatment PlanningPTC58-0654 ,Physics: Treatment PlanningPTC58-0655 ,Biology: Drug and Immunotherapy Combinations Poster Discussion SessionsPTC58-0133 ,Clinics: PediatricsPTC58-0313 ,Physics: Treatment PlanningPTC58-0659 ,Poster AbstractsClinics: CNSPTC58-0290 ,Physics: Commissioning New FacilitiesPTC58-0064 ,Physics: Adaptive TherapyPTC58-0396 ,Physics: Dose Calculation and OptimisationPTC58-0281 ,Physics: Quality Assurance and VerificationPTC58-0427 ,Physics: Quality Assurance and VerificationPTC58-0669 ,General: New Horizons SessionPTC58-0191 ,Physics: Dose Calculation and Optimisation Poster Discussion SessionsPTC58-0217 ,Physics: Quality Assurance and VerificationPTC58-0303 ,Physics: Quality Assurance and VerificationPTC58-0665 ,Clinics: Sarcoma - LymphomaPTC58-0495 ,Physics: Dose Calculation and OptimisationPTC58-0398 ,Physics: Quality Assurance and VerificationPTC58-0667 ,Physics: Quality Assurance and VerificationPTC58-0425 ,Physics: Quality Assurance and VerificationPTC58-0541 ,Physics: Treatment PlanningPTC58-0584 ,Physics: Quality Assurance and VerificationPTC58-0540 ,Biology: Drug and Immunotherapy Combinations Poster Discussion SessionsPTC58-0163 ,Physics: Treatment PlanningPTC58-0224 ,Physics: Treatment PlanningPTC58-0229 ,Clinics: PediatricsPTC58-0249 ,Physics: Beam Delivery and Nozzle Design Poster Discussion SessionsPTC58-0555 ,Clinics: PediatricPTC58-0463 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0556 ,Physics: Absolute and Relative DosimetryPTC58-0498 ,Physics: Commissioning New FacilitiesPTC58-0078 ,Physics: Dose Calculation and OptimisationPTC58-0270 ,Physics: Dose Calculation and OptimisationPTC58-0032 ,Physics: Dose Calculation and OptimisationPTC58-0274 ,Physics: 4D Treatment and DeliveryPTC58-0614 ,Physics: Dose Calculation and OptimisationPTC58-0026 ,Clinics: Head and Neck / EyePTC58-0280 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0091 ,Physics: Treatment PlanningPTC58-0593 ,Biology: Drug and Immunotherapy CombinationsPTC58-0012 ,Physics: Dose Calculation and OptimisationPTC58-0025 ,Physics: Dose Calculation and OptimisationPTC58-0146 ,Clinics: Sarcoma - LymphomaPTC58-0261 ,Physics: Treatment PlanningPTC58-0110 ,Clinics: Lung / Sarcoma / LymphomaPTC58-0733 ,Physics: Quality Assurance and VerificationPTC58-0554 ,Physics: Treatment PlanningPTC58-0597 ,Physics: Dose Calculation and Optimisation Poster Discussion SessionsPTC58-0330 ,Physics: Treatment PlanningPTC58-0115 ,Physics: Treatment PlanningPTC58-0598 ,Physics: Absolute and Relative DosimetryPTC58-0040 ,Physics: Absolute and Relative DosimetryPTC58-0282 ,Biology: Enhanced Biology in Treatment Planning Poster Discussion SessionsPTC58-0399 ,Physics: Absolute and Relative DosimetryPTC58-0283 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0569 ,Clinics: GUPTC58-0647 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0506 ,Physics: Commissioning New FacilitiesPTC58-0047 ,Physics: Dose Calculation and OptimisationPTC58-0067 ,Clinics: GUPTC58-0409 ,Physics: Dose Calculation and OptimisationPTC58-0065 ,Biology: BNCT Poster Discussion SessionsPTC58-0586 ,Physics: Absolute and Relative Dosimetry PTC58-0393 ,Physics: Image GuidancePTC58-0712 ,Physics: Quality Assurance and VerificationPTC58-0645 ,Physics: Treatment PlanningPTC58-0683 ,Biology: BNCT Poster Discussion SessionsPTC58-0107 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0266 ,Physics: Monitoring and Modelling MotionPTC58-0530 ,Biology: BNCT Poster Discussion SessionsPTC58-0341 ,Physics: Commissioning New FacilitiesPTC58-0172 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0456 ,Physics: Dose Calculation and OptimisationPTC58-0170 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0458 ,Physics: Absolute and Relative DosimetryPTC58-0034 ,Physics: Quality Assurance and VerificationPTC58-0417 ,Physics: Quality Assurance and VerificationPTC58-0413 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0492 ,Physics: Dose Calculation and OptimisationPTC58-0168 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0724 ,Physics: Treatment PlanningPTC58-0694 ,Physics: Adaptive TherapyPTC58-0005 ,Physics: Treatment PlanningPTC58-0696 ,Physics: Treatment PlanningPTC58-0453 ,Physics: Adaptive TherapyPTC58-0366 ,Clinics: BreastPTC58-0197 ,Physics: Beam Delivery and Nozzle DesignPTC58-0652 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0017 ,Physics: Treatment PlanningPTC58-0338 ,Clinics: Head and Neck / EyePTC58-0539 ,General: New Horizons SessionPTC58-0390 ,Physics: Image Guidance Poster Discussion SessionsPTC58-0651 ,General: New HorizonsPTC58-0660 ,Physics: Dose Calculation and OptimisationPTC58-0360 ,Physics: Image GuidancePTC58-0297 ,Physics: 4D Treatment and DeliveryPTC58-0147 ,Scientific: RTTPTC58-0388 ,Physics: Dose Calculation and OptimisationPTC58-0484 ,General: New HorizonsPTC58-0301 ,Physics: Dose Calculation and OptimisationPTC58-0485 ,General: New HorizonsPTC58-0304 ,Physics: 4D Treatment and Delivery Poster Discussion SessionsPTC58-0532 ,Clinics: GIPTC58-0575 ,General: New HorizonsPTC58-0306 ,Physics: Quality Assurance and VerificationPTC58-0589 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0344 ,Physics: Quality Assurance and VerificationPTC58-0225 ,Physics: Treatment PlanningPTC58-0381 ,Physics: Quality Assurance and VerificationPTC58-0467 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0585 ,Physics: Commissioning New FacilitiesPTC58-0416 ,Physics: Quality Assurance and VerificationPTC58-0228 ,Physics: Quality Assurance and VerificationPTC58-0348 ,Physics: Dose Calculation and OptimisationPTC58-0234 ,Physics: Quality Assurance and VerificationPTC58-0101 ,Physics: Treatment PlanningPTC58-0386 ,Physics: Dose Calculation and OptimisationPTC58-0118 ,Physics: Treatment PlanningPTC58-0265 ,Physics: Dose Calculation and OptimisationPTC58-0119 ,Clinics: GIPTC58-0218 ,Physics: Treatment PlanningPTC58-0267 ,Physics: Treatment PlanningPTC58-0387 ,Clinics: BreastPTC58-0142 ,Physics: Treatment PlanningPTC58-0269 ,Physics: Beam Delivery and Nozzle DesignPTC58-0620 ,Clinics: PediatricsPTC58-0048 ,Physics: Quality Assurance and VerificationPTC58-0220 ,Physics: Quality Assurance and VerificationPTC58-0461 ,Physics: Treatment PlanningPTC58-0029 ,Physics: Absolute and Relative DosimetryPTC58-0571 ,Physics: Image GuidancePTC58-0046 ,Clinics: GUPTC58-0557 ,Physics: Absolute and Relative DosimetryPTC58-0211 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0131 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0373 ,General: New HorizonsPTC58-0411 ,Physics: Dose Calculation and OptimisationPTC58-0595 ,Clinics: CNS / Skull BasePTC58-0361 ,General: New HorizonsPTC58-0414 ,General: New HorizonsPTC58-0537 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0628 ,Physics: Treatment PlanningPTC58-0271 ,Physics: Commissioning New FacilitiesPTC58-0307 ,Physics: Quality Assurance and VerificationPTC58-0359 ,Physics: Quality Assurance and VerificationPTC58-0354 ,General: New HorizonsPTC58-0419 ,Physics: Treatment PlanningPTC58-0035 ,Biology: BNCTPTC58-0474 ,Clinics: GIPTC58-0460 ,Biology: BNCTPTC58-0596 ,Clinics: GIPTC58-0222 ,Physics: Image GuidancePTC58-0193 ,Clinics: PediatricPTC58-0312 ,Clinics: GUPTC58-0441 ,Clinics: LungPTC58-0701 ,Clinics: EyePTC58-0536 ,Clinics: GUPTC58-0205 ,Physics: Dose Calculation and OptimisationPTC58-0140 ,Clinics: GUPTC58-0208 ,Physics: Dose Calculation and OptimisationPTC58-0020 ,Physics: Image GuidancePTC58-0195 ,Poster AbstractsClinics: CNSPTC58-0717 ,Physics: Quality Assurance and VerificationPTC58-0325 ,Physics: Dose Calculation and OptimisationPTC58-0015 ,Physics: Commissioning New FacilitiesPTC58-0634 ,General: New HorizonsPTC58-0646 ,Physics: Quality Assurance and VerificationPTC58-0566 ,Physics: Dose Calculation and OptimisationPTC58-0134 ,Physics: Dose Calculation and OptimisationPTC58-0376 ,Biology: Mathematical Modelling SimulationPTC58-0462 ,Biology: BNCTPTC58-0567 ,General: New HorizonsPTC58-0527 ,Physics: Treatment PlanningPTC58-0482 ,Clinics: GI, GU, BreastPTC58-0693 ,Physics: Commissioning New FacilitiesPTC58-0518 ,Physics: Quality Assurance and VerificationPTC58-0686 ,Physics: Quality Assurance and VerificationPTC58-0202 ,Physics: Quality Assurance and VerificationPTC58-0322 ,Physics: Quality Assurance and VerificationPTC58-0564 ,Physics: Quality Assurance and VerificationPTC58-0680 ,Physics: Treatment PlanningPTC58-0247 ,Physics: Quality Assurance and VerificationPTC58-0682 ,Physics: Quality Assurance and VerificationPTC58-0440 ,Biology: Translational and BiomarkersPTC58-0514 ,Physics: Beam Delivery and Nozzle Design Poster Discussion SessionsPTC58-0178 ,Clinics: EyePTC58-0520 ,Physics: Absolute and Relative DosimetryPTC58-0231 ,Clinics: Head and Neck / EyePTC58-0424 ,Physics: Absolute and Relative DosimetryPTC58-0471 ,Physics: Absolute and Relative DosimetryPTC58-0356 ,Physics: Dose Calculation and OptimisationPTC58-0491 ,Physics: Dose Calculation and OptimisationPTC58-0250 ,Physics: Commissioning New FacilitiesPTC58-0650 ,Biology: Biology and Clinical InterfacePTC58-0719 ,Physics: Absolute and Relative DosimetryPTC58-0232 ,Physics: Absolute and Relative DosimetryPTC58-0353 ,General: New HorizonsPTC58-0511 ,Physics: Quality Assurance and VerificationPTC58-0219 ,Physics: Absolute and Relative DosimetryPTC58-0238 ,General: New HorizonsPTC58-0512 ,Physics: 4D Treatment and Delivery Poster Discussion SessionsPTC58-0401 ,Clinics: PediatricPTC58-0688 ,Physics: Quality Assurance and VerificationPTC58-0457 ,Physics: Quality Assurance and VerificationPTC58-0214 ,Physics: Quality Assurance and VerificationPTC58-0459 ,General: New HorizonsPTC58-0516 ,Physics: Treatment PlanningPTC58-0372 ,Physics: Treatment PlanningPTC58-0011 ,Physics: Treatment PlanningPTC58-0254 ,Physics: Quality Assurance and VerificationPTC58-0332 ,Clinics: CNS / Skull BasePTC58-0468 ,Biology: Mathematical Modelling SimulationPTC58-0357 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0649 ,Physics: Dose Calculation and OptimisationPTC58-0006 ,Physics: Quality Assurance and VerificationPTC58-0212 ,Physics: Image Guidance Poster Discussion SessionsPTC58-0565 ,Physics: Treatment PlanningPTC58-0018 ,Physics: Treatment PlanningPTC58-0019 ,Clinics: BreastPTC58-0576 ,Clinics: Head and Neck / EyePTC58-0335 ,Clinics: Head and Neck / EyePTC58-0577 ,General: New HorizonsPTC58-0621 ,Physics: Absolute and Relative DosimetryPTC58-0426 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0268 ,Physics: Absolute and Relative DosimetryPTC58-0423 ,Physics: Treatment PlanningPTC58-0184 ,Physics: Quality Assurance and VerificationPTC58-0149 ,Clinics: GIPTC58-0378 ,Clinics: GIPTC58-0257 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0662 ,General: New HorizonsPTC58-0627 ,Physics: Treatment PlanningPTC58-0186 ,Physics: Treatment PlanningPTC58-0185 ,Physics: Quality Assurance and VerificationPTC58-0144 ,Biology: BNCT Poster Discussion SessionsPTC58-0602 ,Physics: Treatment PlanningPTC58-0189 ,Physics: Dose Calculation and OptimisationPTC58-0315 ,Clinics: Head and neckPTC58-0300 ,General: New Horizons SessionPTC58-0347 ,Physics: Image GuidancePTC58-0082 ,Clinics: BreastPTC58-0443 ,Physics: 4D Treatment and Delivery Poster Discussion SessionsPTC58-0629 ,Physics: Adaptive Therapy Poster Discussion SessionsPTC58-0007 ,Physics: Commissioning New FacilitiesPTC58-0472 ,Clinics: GI, GU, BreastPTC58-0515 ,Physics: Dose Calculation and Optimisation Poster Discussion SessionsPTC58-0606 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0450 ,Physics: Absolute and Relative DosimetryPTC58-0657 ,Physics: Dose Calculation and OptimisationPTC58-0551 ,Physics: Treatment PlanningPTC58-0192 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0675 ,Physics: Treatment PlanningPTC58-0194 ,Physics: Dose Calculation and OptimisationPTC58-0544 ,Physics: Treatment PlanningPTC58-0199 ,Physics: Quality Assurance and VerificationPTC58-0037 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0207 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0434 ,Physics: Quality Assurance and VerificationPTC58-0036 ,Physics: Quality Assurance and VerificationPTC58-0278 ,Physics: Quality Assurance and VerificationPTC58-0394 ,Physics: Quality Assurance and VerificationPTC58-0151 ,Physics: Quality Assurance and VerificationPTC58-0154 ,Physics: Dose Calculation and OptimisationPTC58-0428 ,Clinics: BreastPTC58-0116 ,Biology: Enhanced Biology in Treatment Planning Poster Discussion SessionsPTC58-0435 ,Physics: Commissioning New FacilitiesPTC58-0681 ,Physics: Absolute and Relative DosimetryPTC58-0323 ,Physics: Dose Calculation and OptimisationPTC58-0583 ,Physics: Absolute and Relative DosimetryPTC58-0448 ,Clinics: CNS / Skull BasePTC58-0251 ,General: New HorizonsPTC58-0721 ,Physics: Absolute and Relative DosimetryPTC58-0203 ,Physics: Dose Calculation and OptimisationPTC58-0455 ,Physics: 4D Treatment and DeliveryPTC58-0130 ,Physics: Commissioning New FacilitiesPTC58-0679 ,Physics: Absolute and Relative DosimetryPTC58-0329 ,General: New HorizonsPTC58-0604 ,Physics: Absolute and Relative DosimetryPTC58-0449 ,Clinics: CNS / Skull BasePTC58-0132 ,General: New HorizonsPTC58-0607 ,Physics: Quality Assurance and VerificationPTC58-0122 ,Physics: Quality Assurance and VerificationPTC58-0243 ,Physics: Treatment PlanningPTC58-0165 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0437 ,Physics: 4D Treatment and DeliveryPTC58-0377 ,Physics: Quality Assurance and VerificationPTC58-0125 ,Physics: Quality Assurance and VerificationPTC58-0245 ,Physics: Dose Calculation and OptimisationPTC58-0337 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0334 ,Physics: Quality Assurance and VerificationPTC58-0121 ,General: New Horizons SessionPTC58-0563 ,General: New Horizons SessionPTC58-0321 ,Clinics: Head and Neck / EyePTC58-0477 ,Physics: Quality Assurance and VerificationPTC58-0480 ,Clinics: GUPTC58-0010 ,Clinics: EyePTC58-0684 ,Clinics: GUPTC58-0496 ,Clinics: Head and neckPTC58-0676 ,Clinics: GUPTC58-0137 ,Physics: Beam Delivery and Nozzle Design Poster Discussion SessionsPTC58-0256 ,Physics: 4D Treatment and DeliveryPTC58-0117 ,Physics: Absolute and Relative DosimetryPTC58-0552 ,Physics: Absolute and Relative DosimetryPTC58-0310 ,Physics: Absolute and Relative DosimetryPTC58-0672 ,Physics: Absolute and Relative DosimetryPTC58-0436 ,Physics: Dose Calculation and OptimisationPTC58-0452 ,Physics: Dose Calculation and OptimisationPTC58-0331 ,Physics: Commissioning New FacilitiesPTC58-0213 ,Biology: Mathematical Modelling SimulationPTC58-0272 ,Clinics: EyePTC58-0326 ,Physics: Commissioning New FacilitiesPTC58-0568 ,Physics: Dose Calculation and OptimisationPTC58-0444 ,Physics: Quality Assurance and VerificationPTC58-0379 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0095 ,Physics: Treatment PlanningPTC58-0053 ,Physics: Absolute and Relative DosimetryPTC58-0438 ,Physics: Absolute and Relative DosimetryPTC58-0317 ,Physics: Quality Assurance and VerificationPTC58-0497 ,Physics: Quality Assurance and VerificationPTC58-0375 ,Physics: Treatment PlanningPTC58-0056 ,Physics: 4D Treatment and DeliveryPTC58-0124 ,Clinics: GIPTC58-0009 ,Physics: Quality Assurance and VerificationPTC58-0014 ,Physics: Quality Assurance and VerificationPTC58-0374 ,Clinics: LungPTC58-0727 ,General: New Horizons SessionPTC58-0578 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0470 ,Clinics: LungPTC58-0204 ,Clinics: Head and neckPTC58-0227 ,Clinics: LungPTC58-0446 ,Physics: Quality Assurance and VerificationPTC58-0190 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0609 ,Clinics: LungPTC58-0689 ,General: New HorizonsPTC58-0021 ,General: New HorizonsPTC58-0262 ,Biology: BNCT Poster Discussion SessionsPTC58-0081 ,Clinics: GIPTC58-0726 ,General: New HorizonsPTC58-0145 ,Physics: Image GuidancePTC58-0573 ,General: New HorizonsPTC58-0027 ,General: New HorizonsPTC58-0028 ,Biology: Mathematical Modelling and SimulationPTC58-0148 ,Physics: Dose Calculation and OptimisationPTC58-0635 ,Physics: Image GuidancePTC58-0215 ,Physics: Image GuidancePTC58-0336 ,Poster AbstractsClinics: CNSPTC58-0535 ,Physics: Quality Assurance and VerificationPTC58-0187 ,Biology: BNCT Poster Discussion SessionsPTC58-0084 ,General: New Investigator SessionPTC58-0339 ,General: New Horizons SessionPTC58-0420 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0523 ,Biology: BNCT Poster Discussion SessionsPTC58-0088 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0112 ,Physics: Quality Assurance and VerificationPTC58-0182 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0615 ,Physics: Quality Assurance and VerificationPTC58-0080 ,Biology: BNCTPTC58-0085 ,Physics: Adaptive Therapy Poster Discussion SessionsPTC58-0722 ,General: New HorizonsPTC58-0253 ,General: New HorizonsPTC58-0255 ,Clinics: PediatricPTC58-0703 ,General: New HorizonsPTC58-0499 ,Physics: Image Guidance Poster Discussion SessionsPTC58-0380 ,General: New HorizonsPTC58-0259 ,Clinics: GI, GU, BreastPTC58-0288 ,Clinics: GI, GU, BreastPTC58-0045 ,Physics: Absolute and Relative DosimetryPTC58-0619 ,Clinics: PediatricPTC58-0707 ,Physics: Quality Assurance and VerificationPTC58-0196 ,Physics: Quality Assurance and VerificationPTC58-0074 ,Physics: Quality Assurance and VerificationPTC58-0077 ,Biology: BNCT Poster Discussion SessionsPTC58-0073 ,Biology: BNCTPTC58-0075 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0093 ,Clinics: GUPTC58-0161 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0371 ,Physics: Monitoring and Modelling MotionPTC58-0181 ,General: New HorizonsPTC58-0120 ,General: New HorizonsPTC58-0362 ,General: New HorizonsPTC58-0364 ,Physics: Image GuidancePTC58-0473 ,Scientific: RTTPTC58-0641 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0296 ,General: New HorizonsPTC58-0004 ,General: New HorizonsPTC58-0128 ,Clinics: BreastPTC58-0316 ,Physics: 4D Treatment and Delivery Poster Discussion SessionsPTC58-0236 ,General: New HorizonsPTC58-0008 ,General: New Investigator SessionPTC58-0673 ,Physics: Quality Assurance and VerificationPTC58-0167 ,Physics: Quality Assurance and VerificationPTC58-0289 ,Physics: Quality Assurance and VerificationPTC58-0284 ,General: New Horizons SessionPTC58-0522 ,Physics: Quality Assurance and VerificationPTC58-0164 ,Physics: Quality Assurance and VerificationPTC58-0285 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0623 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0502 ,Clinics: GUPTC58-0293 ,Biology: Translational and BiomarkersPTC58-0599 ,Biology: BNCTPTC58-0063 ,Clinics: LungPTC58-0656 ,General: New HorizonsPTC58-0592 ,Biology: BNCT Poster Discussion SessionsPTC58-0092 ,Poster AbstractsClinics: CNSPTC58-0302 ,Physics: Image GuidancePTC58-0464 ,General: New HorizonsPTC58-0352 ,Physics: Image GuidancePTC58-0465 ,General: New HorizonsPTC58-0476 ,Physics: Image GuidancePTC58-0100 ,General: New HorizonsPTC58-0235 ,Biology: Mathematical Modelling and SimulationPTC58-0349 ,Physics: Treatment PlanningPTC58-0094 ,Physics: 4D Treatment and Delivery Poster Discussion SessionsPTC58-0367 ,Physics: Dose Calculation and OptimisationPTC58-0400 ,Biology: Translational and BiomarkersPTC58-0244 ,Physics: Dose Calculation and OptimisationPTC58-0640 ,Biology: Mathematical Modelling and SimulationPTC58-0355 ,General: New Investigator SessionPTC58-0320 ,Physics: Quality Assurance and VerificationPTC58-0057 ,Physics: Quality Assurance and VerificationPTC58-0174 ,Physics: Quality Assurance and VerificationPTC58-0295 ,Physics: Dose Calculation and OptimisationPTC58-0529 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0123 ,Physics: Quality Assurance and VerificationPTC58-0171 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0049 ,Clinics: BreastPTC58-0731 ,General: New HorizonsPTC58-0223 ,General: New HorizonsPTC58-0102 ,General: New HorizonsPTC58-0466 ,Scientific: RTTPTC58-0503 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0389 ,General: New HorizonsPTC58-0108 ,General: New HorizonsPTC58-0109 ,Physics: Commissioning New FacilitiesPTC58-0736 ,Biology: Mathematical Modelling and SimulationPTC58-0343 ,Biology: Mathematical Modelling and SimulationPTC58-0342 ,Clinics: GI, GU, BreastPTC58-0237 ,Physics: Dose Calculation and OptimisationPTC58-0711 ,Biology: Mathematical Modelling and SimulationPTC58-0581 ,Clinics: GI, GU, BreastPTC58-0114 ,Clinics: Base of SkullPTC58-0730 ,Clinics: Head and neckPTC58-0383 ,Clinics: CNS / Skull BasePTC58-0559 ,Clinics: Base of SkullPTC58-0613 ,General: New HorizonsPTC58-0691 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0054 ,General: New HorizonsPTC58-0210 ,Clinics: BreastPTC58-0729 ,General: New HorizonsPTC58-0574 ,Clinics: GI, GU, BreastPTC58-0239 ,Scientific: RTTPTC58-0637 ,General: New HorizonsPTC58-0579 ,Clinics: Lung / Sarcoma / LymphomaPTC58-0176 ,General: New HorizonsPTC58-0699 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0156 ,Biology: Mathematical Modelling and SimulationPTC58-0333 ,Biology: Translational and BiomarkersPTC58-0345 ,Physics: Image GuidancePTC58-0369 ,Physics: Commissioning New FacilitiesPTC58-0509 ,Biology: Mathematical Modelling SimulationPTC58-0658 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0051 ,General: New Investigator SessionPTC58-0548 ,Clinics: GI, GU, BreastPTC58-0241 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0412 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0024 ,Clinics: LungPTC58-0226 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0069 ,General: New HorizonsPTC58-0562 ,General: New HorizonsPTC58-0561 ,General: New HorizonsPTC58-0201 ,Biology: Mathematical Modelling and SimulationPTC58-0439 ,General: New HorizonsPTC58-0445 ,General: New HorizonsPTC58-0324 ,Physics: Image GuidancePTC58-0031 ,Biology: Mathematical Modelling and SimulationPTC58-0558 ,Physics: Image GuidancePTC58-0392 ,Biology: Mathematical Modelling and SimulationPTC58-0678 ,Physics: Beam Delivery and Nozzle DesignPTC58-0090 ,General: New Investigator SessionPTC58-0630 ,Biology: Biological Differences between Carbon / Proton and Photons Carbons / Proton and PhotonPTC58-0524 ,Physics: Commissioning New FacilitiesPTC58-0713 ,Clinics: GI, GU, BreastPTC58-0139 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0248 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0368 ,Biology: Enhanced Biology in Treatment PlanningPTC58-0519 ,General: New Horizons SessionPTC58-0720 ,Physics: Quality Assurance and VerificationPTC58-0083 ,General: New HorizonsPTC58-0311 ,General: New HorizonsPTC58-0674 ,General: New HorizonsPTC58-0553 ,Physics: Image GuidancePTC58-0023 ,Scientific: RTTPTC58-0612 ,General: New HorizonsPTC58-0677 ,Biology: Mathematical Modelling and SimulationPTC58-0545 ,Physics: Dose Calculation and OptimisationPTC58-0601 ,Physics: Dose Calculation and OptimisationPTC58-0725 ,Physics: Quality Assurance and VerificationPTC58-0098 ,Physics: Dose Calculation and OptimisationPTC58-0605 ,Biology: Biological Differences between Carbon / Proton and Photons Carbons / Proton and PhotonPTC58-0517 ,Biology: Translational and Biomarkers Poster Discussion SessionsPTC58-0618 ,Physics: Monitoring and Modelling MotionPTC58-0481 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0071 ,Physics: Adaptive TherapyPTC58-0351 ,Physics: 4D Treatment and DeliveryPTC58-0702 ,Physics: Image GuidancePTC58-0734 ,Physics: Image GuidancePTC58-0611 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0486 ,Physics: Absolute and Relative Dosimetry Poster Discussion SessionsPTC58-0442 ,Biology: Drug and Immunotherapy CombinationsPTC58-0327 ,Clinics: Head and Neck / EyePTC58-0096 ,Clinics: LungPTC58-0159 ,Physics: Treatment PlanningPTC58-0708 ,General: New HorizonsPTC58-0097 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0350 ,Biology: Biological Differences between Carbon / Proton and Photons Carbons / Proton and PhotonPTC58-0016 ,Physics: Adaptive TherapyPTC58-0104 ,Physics: Absolute and Relative Dosimetry Poster Discussion SessionsPTC58-0433 ,Physics: Image GuidancePTC58-0608 ,Biology: Translational and Biomarkers Poster Discussion SessionsPTC58-0610 ,Clinics: Head and neckPTC58-0058 ,Physics: Treatment PlanningPTC58-0715 ,Clinics: Head and neckPTC58-0298 ,Clinics: EyePTC58-0099 ,General: New HorizonsPTC58-0086 ,General: New HorizonsPTC58-0089 ,Clinics: Lung / Sarcoma / LymphomaPTC58-0200 ,Poster AbstractsClinics: CNSPTC58-0157 ,Clinics: LungPTC58-0141 ,Clinics: LungPTC58-0260 ,Clinics: LungPTC58-0264 ,Physics: Image GuidancePTC58-0513 ,Physics: Image GuidancePTC58-0631 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0469 ,Biology: BNCT Poster Discussion SessionsPTC58-0384 ,Physics: Image GuidancePTC58-0639 ,Clinics: PediatricsPTC58-0700 ,Clinics: LungPTC58-0136 ,Clinics: BreastPTC58-0706 ,General: New HorizonsPTC58-0079 ,Biology: Drug and Immunotherapy Combinations Poster Discussion SessionsPTC58-0406 ,Clinics: Base of SkullPTC58-0382 ,Physics: Image GuidancePTC58-0624 ,Physics: Beam Delivery and Nozzle DesignPTC58-0173 ,Biology: Drug and Immunotherapy CombinationsPTC58-0358 ,Poster AbstractsClinics: CNSPTC58-0690 ,General: New HorizonsPTC58-0061 ,Clinics: Lung / Sarcoma / LymphomaPTC58-0580 ,Physics: Monitoring and Modelling MotionPTC58-0162 ,Physics: Adaptive TherapyPTC58-0550 ,Physics: Adaptive TherapyPTC58-0430 ,Clinics: Lung / Sarcoma / LymphomaPTC58-0103 ,General: New Investigator SessionPTC58-0252 ,Physics: Quality Assurance and VerificationPTC58-0704 ,Physics: Image GuidancePTC58-0418 ,Clinics: Base of SkullPTC58-0572 ,Clinics: Lung / Sarcoma / LymphomaPTC58-0106 ,Physics: Beam Delivery and Nozzle DesignPTC58-0022 ,Physics: Monitoring and Modelling MotionPTC58-0279 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0447 ,Physics: Treatment PlanningPTC58-0622 ,Clinics: PediatricsPTC58-0644 ,Biology: Biology and Clinical InterfacePTC58-0490 ,Clinics: CNS / Skull BasePTC58-0716 ,General: New HorizonsPTC58-0292 ,Biology: Biological Differences between Carbon / Proton and Photons Carbons / Proton and PhotonPTC58-0570 ,General: New HorizonsPTC58-0059 ,Physics: Quality Assurance and VerificationPTC58-0710 ,Biology: Biological Differences between Carbon / Proton and Photons Carbons / Proton and PhotonPTC58-0216 ,Physics: Image GuidancePTC58-0404 ,Physics: Image GuidancePTC58-0525 ,Physics: Image GuidancePTC58-0526 ,Poster AbstractsClinics: CNSPTC58-0328 ,Clinics: LungPTC58-0070 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0135 ,Biology: BNCT Poster Discussion SessionsPTC58-0391 ,Physics: Treatment PlanningPTC58-0510 ,Physics: Treatment PlanningPTC58-0636 ,Physics: Treatment PlanningPTC58-0638 ,Physics: Image GuidancePTC58-0408 ,Physics: Absolute and Relative Dosimetry Poster Discussion SessionsPTC58-0632 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0318 ,Biology: Enhanced Biology in Treatment PlanningPTC58-0246 ,Clinics: PediatricsPTC58-0504 ,General: New HorizonsPTC58-0160 ,Physics: Image Guidance Poster Discussion SessionsPTC58-0076 ,Physics: Monitoring and Modelling MotionPTC58-0143 ,Biology: Mathematical Modelling and SimulationPTC58-0718 ,Physics: Image GuidancePTC58-0671 ,Clinics: LungPTC58-0183 ,Physics: Image GuidancePTC58-0670 ,Report ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0422 ,Biology: Biological Differences between Carbon / Proton and Photons Carbons / Proton and PhotonPTC58-0129 ,Physics: Adaptive Therapy Poster Discussion SessionsPTC58-0705 ,Biology: Enhanced Biology in Treatment PlanningPTC58-0258 ,General: New HorizonsPTC58-0030 ,General: New HorizonsPTC58-0150 ,Biology: Biology and Clinical InterfacePTC58-0479 ,General: New HorizonsPTC58-0153 ,Clinics: PediatricPTC58-0087 ,General: New HorizonsPTC58-0152 ,General: New HorizonsPTC58-0155 ,General: New HorizonsPTC58-0033 ,General: New HorizonsPTC58-0158 ,Physics: Image GuidancePTC58-0429 ,Biology: Translational and BiomarkersPTC58-0287 ,Physics: Adaptive TherapyPTC58-0403 ,Physics: Image GuidancePTC58-0309 - Published
- 2020
17. Childhood Myelodysplastic Syndromes Treated with Acute Myeloid Leukemia Regimens
- Author
-
Hasle, H., Kerndrup, G., Büchner, T., editor, Schellong, G., editor, Ritter, J., editor, Creutzig, U., editor, Hiddemann, W., editor, and Wörmann, B., editor
- Published
- 1997
- Full Text
- View/download PDF
18. Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes
- Author
-
Sahoo S. S., Pastor V. B., Goodings C., Voss R. K., Kozyra E. J., Szvetnik A., Noellke P., Dworzak M., Stary J., Locatelli F., Masetti R., Schmugge M., De Moerloose B., Catala A., Kallay K., Turkiewicz D., Hasle H., Buechner J., Jahnukainen K., Ussowicz M., Polychronopoulou S., Smith O. P., Fabri O., Barzilai S., de Haas V., Baumann I., Schwarz-Furlan S., Moerloose B. D., Smith O., Haas V. D., Gohring G., Niemeyer C., Nebral K., Simonitsch-Kluppp I., Paepe P. D., Van Roy N., Campr V., Zemanova Z., Clasen-Linde E., Plesner T., Schlegelberger B., Rudelius M., Manola K., Stefanaki K., Csomor J., Andrikovics H., Betts D., O'Sullivan M., Zohar Y., Jeison M., Vito R. D., Pasquali F., Maldyk J., Haus O., Alaiz H., Kjollerstrom P., Lemos L. M., Bodova I., Cermak M., Plank L., Gazic B., Kavcic M., Podgornik H., Ros M. L., Cervera J., Gengler C., Tchinda J., Beverloo B., Leguit R., Niewisch M. R., Sauer M. G., Burkhardt B., Lang P., Bader P., Beier R., Muller I., Albert M. H., Meisel R., Schulz A., Cario G., Panda P. K., Wehrle J., Hirabayashi S., Derecka M., Durruthy-Durruthy R., Yoshimi-Noellke A., Ku M., Lebrecht D., Erlacher M., Flotho C., Strahm B., Niemeyer C. M., Wlodarski M. W., Sahoo S.S., Pastor V.B., Goodings C., Voss R.K., Kozyra E.J., Szvetnik A., Noellke P., Dworzak M., Stary J., Locatelli F., Masetti R., Schmugge M., De Moerloose B., Catala A., Kallay K., Turkiewicz D., Hasle H., Buechner J., Jahnukainen K., Ussowicz M., Polychronopoulou S., Smith O.P., Fabri O., Barzilai S., de Haas V., Baumann I., Schwarz-Furlan S., Moerloose B.D., Smith O., Haas V.D., Gohring G., Niemeyer C., Nebral K., Simonitsch-Kluppp I., Paepe P.D., Van Roy N., Campr V., Zemanova Z., Clasen-Linde E., Plesner T., Schlegelberger B., Rudelius M., Manola K., Stefanaki K., Csomor J., Andrikovics H., Betts D., O'Sullivan M., Zohar Y., Jeison M., Vito R.D., Pasquali F., Maldyk J., Haus O., Alaiz H., Kjollerstrom P., Lemos L.M., Bodova I., Cermak M., Plank L., Gazic B., Kavcic M., Podgornik H., Ros M.L., Cervera J., Gengler C., Tchinda J., Beverloo B., Leguit R., Niewisch M.R., Sauer M.G., Burkhardt B., Lang P., Bader P., Beier R., Muller I., Albert M.H., Meisel R., Schulz A., Cario G., Panda P.K., Wehrle J., Hirabayashi S., Derecka M., Durruthy-Durruthy R., Yoshimi-Noellke A., Ku M., Lebrecht D., Erlacher M., Flotho C., Strahm B., Niemeyer C.M., Wlodarski M.W., and Clinical Genetics
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Monosomy ,Adolescent ,Somatic cell ,Medizin ,Bone Marrow Cells ,Kaplan-Meier Estimate ,General Biochemistry, Genetics and Molecular Biology ,Germline ,Article ,Clonal Evolution ,Germline mutation ,SDG 3 - Good Health and Well-being ,Internal medicine ,medicine ,Humans ,Child ,Germ-Line Mutation ,Chromosome 7 (human) ,Cytopenia ,clonal hemopoiesis ,business.industry ,Myelodysplastic syndromes ,Tumor Suppressor Proteins ,Intracellular Signaling Peptides and Proteins ,High-Throughput Nucleotide Sequencing ,Infant ,General Medicine ,medicine.disease ,GATA2 Transcription Factor ,SAMD9 and SAMD9L mutations, Pediatric Myelodysplastic syndromes ,medicine.anatomical_structure ,HEK293 Cells ,Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA ,Child, Preschool ,Myelodysplastic Syndromes ,Female ,Bone marrow ,Clonal Hematopoiesis ,Single-Cell Analysis ,business - Abstract
Germline SAMD9 and SAMD9L mutations (SAMD9/9Lmut) predispose to myelodysplastic syndromes (MDS) with propensity for somatic rescue. In this study, we investigated a clinically annotated pediatric MDS cohort (n = 669) to define the prevalence, genetic landscape, phenotype, therapy outcome and clonal architecture of SAMD9/9L syndromes. In consecutively diagnosed MDS, germline SAMD9/9Lmut accounted for 8% and were mutually exclusive with GATA2 mutations present in 7% of the cohort. Among SAMD9/9Lmut cases, refractory cytopenia was the most prevalent MDS subtype (90%); acquired monosomy 7 was present in 38%; constitutional abnormalities were noted in 57%; and immune dysfunction was present in 28%. The clinical outcome was independent of germline mutations. In total, 67 patients had 58 distinct germline SAMD9/9Lmut clustering to protein middle regions. Despite inconclusive in silico prediction, 94% of SAMD9/9Lmut suppressed HEK293 cell growth, and mutations expressed in CD34+ cells induced overt cell death. Furthermore, we found that 61% of SAMD9/9Lmut patients underwent somatic genetic rescue (SGR) resulting in clonal hematopoiesis, of which 95% was maladaptive (monosomy 7 ± cancer mutations), and 51% had adaptive nature (revertant UPD7q, somatic SAMD9/9Lmut). Finally, bone marrow single-cell DNA sequencing revealed multiple competing SGR events in individual patients. Our findings demonstrate that SGR is common in SAMD9/9Lmut MDS and exemplify the exceptional plasticity of hematopoiesis in children. This analysis of a large, clinically annotated cohort of individuals with predisposition to myelodysplastic syndromes reveals insights into the genetic determinants of disease progression and their relationship with clinical manifestations and therapy outcome.
- Published
- 2021
19. The clinical relevance of minor paroxysmal nocturnal hemoglobinuria clones in refractory cytopenia of childhood: a prospective study by EWOG-MDS
- Author
-
Aalbers, A M, van der Velden, V H J, Yoshimi, A, Fischer, A, Noellke, P, Zwaan, C M, Baumann, I, Beverloo, H B, Dworzak, M, Hasle, H, Locatelli, F, De Moerloose, B, Göhring, G, Schmugge, M, Stary, J, Zecca, M, Langerak, A W, van Dongen, J J M, Pieters, R, Niemeyer, C M, and van den Heuvel-Eibrink, M M
- Published
- 2014
- Full Text
- View/download PDF
20. P47 - Topic: AS07-Singular Entities/Subtypes/AS07c-Hereditary MDS including predisposition syndromes: HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN AND ADOLESCENTS WITH GATA2-RELATED MYELODYSPLASTIC SYNDROME
- Author
-
Bortnick, R., Wlodarski, M., De Haas, V., De Moerloose, B., Dworzak, M., Hasle, H., Masetti, R., Stary, J., Turkiewicz, D., Ussowicz, M., Kozyra, E., Albert, M., Bader, P., Bordon, V., Cario, G., Beier, R., Schulte, J., Bresters, D., Mueller, I., Pichler, H., Sedlacek, P., Sauer, M., Zecca, M., Göhring, G., Yoshimi, A., Noellke, P., Erlacher, M., Locatelli, F., Niemeyer, C., and Strahm, B.
- Published
- 2021
- Full Text
- View/download PDF
21. O27 - Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: OUTCOMES OF RELAPSED JUVENILE MYELOMONOCYTIC LEUKEMIA: THE ROLE OF SECOND HEMATOPOIETIC STEM CELL TRANSPLANTATION
- Author
-
Yoshimi, A., Vinci, L., Flotho, C., Noellke, P., Erlacher, M., Lebrecht, D., Masetti, R., De Haas, V., De Moerloose, B., Dworzak, M., Hasle, H., Schmugge, M., Stary, J., Turkiewicz, D., Ussowicz, M., Catala, A., Buechner, J., Jahnukainen, K., Kállay, K., Fabri, O., Smith, O., Göhring, G., Locatelli, F., Strahm, B., and Niemeyer, C.
- Published
- 2021
- Full Text
- View/download PDF
22. O05 - Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: SOMATIC GENETIC RESCUE IN SAMD9/SAMD9L MDS PREDISPOSITION SYNDROMES
- Author
-
Sahoo, S., Pastor, V., Goodings, C., Noellke, P., Dworzak, M., Stary, J., Locatelli, F., Masetti, R., Schmugge, M., De Moerloose, B., Catala, A., Kállay, K., Turkiewicz, D., Hasle, H., Buechner, J., Jahnukainen, K., Ussowicz, M., Polychronopoulou, S., Smith, O., Fabri, O., Barzilai, S., De Haas, V., Baumann, I., Schwarz-Furlan, S., Göhring, G., Yoshimi, A., Flotho, C., Strahm, B., Erlacher, M., Niemeyer, C., and Wlodarski, M.
- Published
- 2021
- Full Text
- View/download PDF
23. Topic: AS07-Singular Entities/Subtypes/AS07c-Hereditary MDS including predisposition syndromes
- Author
-
Bortnick, R., primary, Wlodarski, M., additional, De Haas, V., additional, De Moerloose, B., additional, Dworzak, M., additional, Hasle, H., additional, Masetti, R., additional, Stary, J., additional, Turkiewicz, D., additional, Ussowicz, M., additional, Kozyra, E., additional, Albert, M., additional, Bader, P., additional, Bordon, V., additional, Cario, G., additional, Beier, R., additional, Schulte, J., additional, Bresters, D., additional, Mueller, I., additional, Pichler, H., additional, Sedlacek, P., additional, Sauer, M., additional, Zecca, M., additional, Göhring, G., additional, Yoshimi, A., additional, Noellke, P., additional, Erlacher, M., additional, Locatelli, F., additional, Niemeyer, C., additional, and Strahm, B., additional
- Published
- 2021
- Full Text
- View/download PDF
24. Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment
- Author
-
Yoshimi, A., primary, Vinci, L., additional, Flotho, C., additional, Noellke, P., additional, Erlacher, M., additional, Lebrecht, D., additional, Masetti, R., additional, De Haas, V., additional, De Moerloose, B., additional, Dworzak, M., additional, Hasle, H., additional, Schmugge, M., additional, Stary, J., additional, Turkiewicz, D., additional, Ussowicz, M., additional, Catala, A., additional, Buechner, J., additional, Jahnukainen, K., additional, Kállay, K., additional, Fabri, O., additional, Smith, O., additional, Göhring, G., additional, Locatelli, F., additional, Strahm, B., additional, and Niemeyer, C., additional
- Published
- 2021
- Full Text
- View/download PDF
25. Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution
- Author
-
Sahoo, S., primary, Pastor, V., additional, Goodings, C., additional, Noellke, P., additional, Dworzak, M., additional, Stary, J., additional, Locatelli, F., additional, Masetti, R., additional, Schmugge, M., additional, De Moerloose, B., additional, Catala, A., additional, Kállay, K., additional, Turkiewicz, D., additional, Hasle, H., additional, Buechner, J., additional, Jahnukainen, K., additional, Ussowicz, M., additional, Polychronopoulou, S., additional, Smith, O., additional, Fabri, O., additional, Barzilai, S., additional, De Haas, V., additional, Baumann, I., additional, Schwarz-Furlan, S., additional, Göhring, G., additional, Yoshimi, A., additional, Flotho, C., additional, Strahm, B., additional, Erlacher, M., additional, Niemeyer, C., additional, and Wlodarski, M., additional
- Published
- 2021
- Full Text
- View/download PDF
26. Skeletal adverse events in childhood cancer survivors:an Adult Life after Childhood Cancer in Scandinavia cohort study
- Author
-
Oskarsson, T. (Trausti), Duun-Henriksen, A. K. (Anne Katrine), Bautz, A. (Andrea), Montgomery, S. (Scott), Harila-Saari, A. (Arja), Petersen, C. (Cecilia), Niinimäki, R. (Riitta), Madanat-Harjuoja, L. (Laura), Tryggvadóttir, L. (Laufey), Sällfors Holmqvist, A. (Anna), Hasle, H. (Henrik), Heyman, M. (Mats), Winther, J. F. (Jeanette Falck), and ALiCCS study group, . ()
- Subjects
skeletal adverse events ,childhood cancer ,late effects ,ALiCCS ,survivorship - Abstract
The dynamic growth of the skeleton during childhood and adolescence renders it vulnerable to adverse effects of cancer treatment. The lifetime risk and patterns of skeletal morbidity have not been described in a population-based cohort of childhood cancer survivors. A cohort of 26 334 1-year cancer survivors diagnosed before 20 years of age was identified from the national cancer registries of Denmark, Finland, Iceland and Sweden as well as a cohort of 127 531 age- and sex-matched comparison subjects randomly selected from the national population registries in each country. The two cohorts were linked with data from the national hospital registries and the observed numbers of first-time hospital admissions for adverse skeletal outcomes among childhood cancer survivors were compared to the expected numbers derived from the comparison cohort. In total, 1987 childhood cancer survivors had at least one hospital admission with a skeletal adverse event as discharge diagnosis, yielding a rate ratio (RR) of 1.35 (95% confidence interval, 1.29-1.42). Among the survivors, we observed an increased risk for osteonecrosis with a RR of 25.9 (15.0-44.5), osteoporosis, RR 4.53 (3.28-6.27), fractures, RR 1.27 (1.20-1.34), osteochondropathies, RR 1.57 (1.28-1.92) and osteoarthrosis, RR 1.48 (1.28-1.72). The hospitalization risk for any skeletal adverse event was higher among survivors up to the age of 60 years, but the lifetime pattern was different for each type of skeletal adverse event. Understanding the different lifetime patterns and identification of high-risk groups is crucial for developing strategies to optimize skeletal health in childhood cancer survivors.
- Published
- 2021
27. OUTCOMES OF RELAPSED JUVENILE MYELOMONOCYTIC LEUKEMIA: THE ROLE OF SECOND HEMATOPOIETIC STEM CELL TRANSPLANTATION
- Author
-
Yoshimi, A., Vinci, L., Flotho, C., Noellke, P., Erlacher, M., Lebrecht, D., Masetti, R., Haas, V., Moerloose, B., Dworzak, M., Hasle, H., Schmugge, M., Stary, J., Turkiewicz, D., Marek Ussowicz, Catala, A., Buechner, J., Jahnukainen, K., Kallay, K., Fabri, O., Smith, O., Goehring, G., Locatelli, F., Strahm, B., and Niemeyer, C.
- Published
- 2021
28. Publisher Correction: Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes (Nature Medicine, (2021), 27, 10, (1806-1817), 10.1038/s41591-021-01511-6)
- Author
-
Sahoo, S. S., Pastor, V. B., Goodings, C., Voss, R. K., Kozyra, E. J., Szvetnik, A., Noellke, P., Dworzak, M., Stary, J., Locatelli, Franco, Masetti, R., Schmugge, M., De Moerloose, B., Catala, A., Kallay, K., Turkiewicz, D., Hasle, H., Buechner, J., Jahnukainen, K., Ussowicz, M., Polychronopoulou, S., Smith, O. P., Fabri, O., Barzilai, S., de Haas, V., Baumann, I., Schwarz-Furlan, S., Smith, O., Haas, V. D., Gohring, G., Niemeyer, C., Nebral, K., Simonitsch-Kluppp, I., Paepe, P. D., Van Roy, N., Campr, V., Zemanova, Z., Clasen-Linde, E., Plesner, T., Schlegelberger, B., Rudelius, M., Manola, K., Stefanaki, K., Csomor, J., Andrikovics, H., Betts, D., O'Sullivan, M., Zohar, Y., Jeison, M., Vito, R. D., Pasquali, F., Maldyk, J., Haus, O., Alaiz, H., Kjollerstrom, P., Lemos, L. M., Bodova, I., Cermak, M., Plank, L., Gazic, B., Kavcic, M., Podgornik, H., Ros, M. L., Cervera, J., Gengler, C., Tchinda, J., Beverloo, B., Leguit, R., Niewisch, M. R., Sauer, M. G., Burkhardt, B., Lang, P., Bader, P., Beier, R., Muller, I., Albert, M. H., Meisel, R., Schulz, A., Cario, G., Panda, P. K., Wehrle, J., Hirabayashi, S., Derecka, M., Durruthy-Durruthy, R., Yoshimi-Noellke, A., Ku, M., Lebrecht, D., Erlacher, M., Flotho, C., Strahm, B., Niemeyer, C. M., and Wlodarski, M. W.
- Subjects
Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA ,SAMD9/SAMD9L syndromes - Published
- 2021
29. TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study
- Author
-
Meijer, A, Diepstraten, FA, Langer, T, Broer, L, Domingo, IK, Clemens, E, Uitterlinden, AG, de Vries, ACH, van Grotel, M, Vermeij, WP, Ozinga, RA, Binder, H, Byrne, J, van Dulmen-den Broeder, E, Garrè, ML, Grabow, D, Kaatsch, P, Kaiser, M, Kenborg, L, Falck-Winther, J, Rechnitzer, C, Hasle, H, Kepak, T, Kepakova, K, Tissing, WJE, van der Kooi, ALF, Kremer, LC, Kruseova, J, Pluijm, SMF, Kuehni, CF, van der Pal, H, Parfitt, R, Spix, C, Hesping, A, Deuster, D, Matulat, P, Calaminus, G, Hoetink, AE, Elsner, S, Gebauer, J, Haupt, R, Lackner, H, Blattmann, C, Neggers, SJCMM, Rassekh, SR, Wright, GEB, Brooks, B, Nagtegaal, AP, Drögemöller, BI, Ross, CJD, Bhavsar, AP, am Zehnhoff-Dinnesen, A, Carleton, BC, Zolk, O, van den Heuvel-Eibrink, M, Meijer, A, Diepstraten, FA, Langer, T, Broer, L, Domingo, IK, Clemens, E, Uitterlinden, AG, de Vries, ACH, van Grotel, M, Vermeij, WP, Ozinga, RA, Binder, H, Byrne, J, van Dulmen-den Broeder, E, Garrè, ML, Grabow, D, Kaatsch, P, Kaiser, M, Kenborg, L, Falck-Winther, J, Rechnitzer, C, Hasle, H, Kepak, T, Kepakova, K, Tissing, WJE, van der Kooi, ALF, Kremer, LC, Kruseova, J, Pluijm, SMF, Kuehni, CF, van der Pal, H, Parfitt, R, Spix, C, Hesping, A, Deuster, D, Matulat, P, Calaminus, G, Hoetink, AE, Elsner, S, Gebauer, J, Haupt, R, Lackner, H, Blattmann, C, Neggers, SJCMM, Rassekh, SR, Wright, GEB, Brooks, B, Nagtegaal, AP, Drögemöller, BI, Ross, CJD, Bhavsar, AP, am Zehnhoff-Dinnesen, A, Carleton, BC, Zolk, O, and van den Heuvel-Eibrink, M
- Abstract
Background: Ototoxicity (hearing loss, tinnitus and/or vertigo) is a serious adverse event of cisplatin treatment in children with cancer. The heterogeneity in ototoxicity occurrence after similar treatment suggests a role for genetic susceptibility. This study investigated the association between carriership of novel single nucleotide polymorphisms (SNPs) and cisplatin-induced hearing loss (CIHL) in childhood cancer patients.Material and methods: The discovery cohort included cisplatin treated, non-cranial irradiated pediatric cancer patients within the European PanCareLIFE (PCL) study (N=390). CIHL at end of cancer treatment was defined as Muenster grade >=2b, assessed by pure tone audiometry. DNA was genotyped using the Infinium© Global Screening Array. Logistic regression models were applied including age at diagnosis, sex, cisplatin total cumulative dose and principal components 1-4, assuming an additive effect of the minor allele. Replication of the findings was performed in two independent, similarly treated cohorts (N=192 and N=188). Functional validation experiments in cultured human HeLa cell lines were performed to determine the effect of knockdown of the SNPs nearest identified gene on cisplatin-induced toxicity.Results: In the PCL discovery cohort, 8 SNPs reached a suggestive significance of P<1.0x10-5. One variant (rs893507) within the TCERG1L gene showed evidence of replication (P=0.01) in the Canadian first replication cohort. Analysis in the PCL second replication cohort confirmed this finding (P=1.0x10-4). The combined analysis showed that carriership of the C-allele of this newly discovered variant increases the odds of CIHL with 3.11-fold (P=5.3x10-10, 95% CI 2.2-4.5). Modulating TCERG1L expression significantly altered cell viability in response to cisplatin treatment, where TCERG1L overexpression and silencing protected and sensitized cells to cisplatin toxicity, respectively.Discussion: Children with cancer who carry a variant in the TCERG1L g
- Published
- 2021
30. Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome
- Author
-
Bortnick, R., Wlodarski, M., de Haas, V., De Moerloose, B., Dworzak, M., Hasle, H., Masetti, R., Stary, J., Turkiewicz, D., Ussowicz, M., Kozyra, E., Albert, M., Bader, P., Bordon, V., Cario, G., Beier, R., Schulte, J., Bresters, D., Muller, I., Pichler, H., Sedlacek, P., Sauer, M. G., Zecca, M., Gohring, G., Yoshimi, A., Noellke, P., Erlacher, M., Locatelli, Franco, Niemeyer, C. M., Strahm, B., Locatelli F. (ORCID:0000-0002-7976-3654), Bortnick, R., Wlodarski, M., de Haas, V., De Moerloose, B., Dworzak, M., Hasle, H., Masetti, R., Stary, J., Turkiewicz, D., Ussowicz, M., Kozyra, E., Albert, M., Bader, P., Bordon, V., Cario, G., Beier, R., Schulte, J., Bresters, D., Muller, I., Pichler, H., Sedlacek, P., Sauer, M. G., Zecca, M., Gohring, G., Yoshimi, A., Noellke, P., Erlacher, M., Locatelli, Franco, Niemeyer, C. M., Strahm, B., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
GATA2 deficiency is a heterogeneous multi-system disorder characterized by a high risk of developing myelodysplastic syndrome (MDS) and myeloid leukemia. We analyzed the outcome of 65 patients reported to the registry of the European Working Group (EWOG) of MDS in childhood carrying a germline GATA2 mutation (GATA2mut) who had undergone hematopoietic stem cell transplantation (HSCT). At 5 years the probability of overall survival and disease-free survival (DFS) was 75% and 70%, respectively. Non-relapse mortality and relapse equally contributed to treatment failure. There was no evidence of increased incidence of graft-versus-host-disease or excessive rates of infections or organ toxicities. Advanced disease and monosomy 7 (−7) were associated with worse outcome. Patients with refractory cytopenia of childhood (RCC) and normal karyotype showed an excellent outcome (DFS 90%) compared to RCC and −7 (DFS 67%). Comparing outcome of GATA2mut with GATA2wt patients, there was no difference in DFS in patients with RCC and normal karyotype. The same was true for patients with −7 across morphological subtypes. We demonstrate that HSCT outcome is independent of GATA2 germline mutations in pediatric MDS suggesting the application of standard MDS algorithms and protocols. Our data support considering HSCT early in the course of GATA2 deficiency in young individuals.
- Published
- 2021
31. Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes
- Author
-
Sahoo, S. S., Pastor, V. B., Goodings, C., Voss, R. K., Kozyra, E. J., Szvetnik, A., Noellke, P., Dworzak, M., Stary, J., Locatelli, Franco, Masetti, R., Schmugge, M., De Moerloose, B., Catala, A., Kallay, K., Turkiewicz, D., Hasle, H., Buechner, J., Jahnukainen, K., Ussowicz, M., Polychronopoulou, S., Smith, O. P., Fabri, O., Barzilai, S., de Haas, V., Baumann, I., Schwarz-Furlan, S., Smith, O., Haas, V. D., Gohring, G., Niemeyer, C., Nebral, K., Simonitsch-Kluppp, I., Paepe, P. D., Van Roy, N., Campr, V., Zemanova, Z., Clasen-Linde, E., Plesner, T., Schlegelberger, B., Rudelius, M., Manola, K., Stefanaki, K., Csomor, J., Andrikovics, H., Betts, D., O'Sullivan, M., Zohar, Y., Jeison, M., Vito, R. D., Pasquali, F., Maldyk, J., Haus, O., Alaiz, H., Kjollerstrom, P., Lemos, L. M., Bodova, I., Cermak, M., Plank, L., Gazic, B., Kavcic, M., Podgornik, H., Ros, M. L., Cervera, J., Gengler, C., Tchinda, J., Beverloo, B., Leguit, R., Niewisch, M. R., Sauer, M. G., Burkhardt, B., Lang, P., Bader, P., Beier, R., Muller, I., Albert, M. H., Meisel, R., Schulz, A., Cario, G., Panda, P. K., Wehrle, J., Hirabayashi, S., Derecka, M., Durruthy-Durruthy, R., Yoshimi-Noellke, A., Ku, M., Lebrecht, D., Erlacher, M., Flotho, C., Strahm, B., Niemeyer, C. M., Wlodarski, M. W., Locatelli F. (ORCID:0000-0002-7976-3654), Sahoo, S. S., Pastor, V. B., Goodings, C., Voss, R. K., Kozyra, E. J., Szvetnik, A., Noellke, P., Dworzak, M., Stary, J., Locatelli, Franco, Masetti, R., Schmugge, M., De Moerloose, B., Catala, A., Kallay, K., Turkiewicz, D., Hasle, H., Buechner, J., Jahnukainen, K., Ussowicz, M., Polychronopoulou, S., Smith, O. P., Fabri, O., Barzilai, S., de Haas, V., Baumann, I., Schwarz-Furlan, S., Smith, O., Haas, V. D., Gohring, G., Niemeyer, C., Nebral, K., Simonitsch-Kluppp, I., Paepe, P. D., Van Roy, N., Campr, V., Zemanova, Z., Clasen-Linde, E., Plesner, T., Schlegelberger, B., Rudelius, M., Manola, K., Stefanaki, K., Csomor, J., Andrikovics, H., Betts, D., O'Sullivan, M., Zohar, Y., Jeison, M., Vito, R. D., Pasquali, F., Maldyk, J., Haus, O., Alaiz, H., Kjollerstrom, P., Lemos, L. M., Bodova, I., Cermak, M., Plank, L., Gazic, B., Kavcic, M., Podgornik, H., Ros, M. L., Cervera, J., Gengler, C., Tchinda, J., Beverloo, B., Leguit, R., Niewisch, M. R., Sauer, M. G., Burkhardt, B., Lang, P., Bader, P., Beier, R., Muller, I., Albert, M. H., Meisel, R., Schulz, A., Cario, G., Panda, P. K., Wehrle, J., Hirabayashi, S., Derecka, M., Durruthy-Durruthy, R., Yoshimi-Noellke, A., Ku, M., Lebrecht, D., Erlacher, M., Flotho, C., Strahm, B., Niemeyer, C. M., Wlodarski, M. W., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Germline SAMD9 and SAMD9L mutations (SAMD9/9Lmut) predispose to myelodysplastic syndromes (MDS) with propensity for somatic rescue. In this study, we investigated a clinically annotated pediatric MDS cohort (n = 669) to define the prevalence, genetic landscape, phenotype, therapy outcome and clonal architecture of SAMD9/9L syndromes. In consecutively diagnosed MDS, germline SAMD9/9Lmut accounted for 8% and were mutually exclusive with GATA2 mutations present in 7% of the cohort. Among SAMD9/9Lmut cases, refractory cytopenia was the most prevalent MDS subtype (90%); acquired monosomy 7 was present in 38%; constitutional abnormalities were noted in 57%; and immune dysfunction was present in 28%. The clinical outcome was independent of germline mutations. In total, 67 patients had 58 distinct germline SAMD9/9Lmut clustering to protein middle regions. Despite inconclusive in silico prediction, 94% of SAMD9/9Lmut suppressed HEK293 cell growth, and mutations expressed in CD34+ cells induced overt cell death. Furthermore, we found that 61% of SAMD9/9Lmut patients underwent somatic genetic rescue (SGR) resulting in clonal hematopoiesis, of which 95% was maladaptive (monosomy 7 ± cancer mutations), and 51% had adaptive nature (revertant UPD7q, somatic SAMD9/9Lmut). Finally, bone marrow single-cell DNA sequencing revealed multiple competing SGR events in individual patients. Our findings demonstrate that SGR is common in SAMD9/9Lmut MDS and exemplify the exceptional plasticity of hematopoiesis in children.
- Published
- 2021
32. The variable biological signature of refractory cytopenia of childhood (RCC), a retrospective EWOG-MDS study
- Author
-
de Winter, D. T. C., Langerak, A. W., te Marvelde, J., Dworzak, M. N., De Moerloose, B., Stary, J., Locatelli, Franco, Hasle, H., de Vries, A. C. H., Schmugge, M., Niemeyer, C. M., van den Heuvel-Eibrink, M. M., van der Velden, V. H. J., Locatelli F. (ORCID:0000-0002-7976-3654), de Winter, D. T. C., Langerak, A. W., te Marvelde, J., Dworzak, M. N., De Moerloose, B., Stary, J., Locatelli, Franco, Hasle, H., de Vries, A. C. H., Schmugge, M., Niemeyer, C. M., van den Heuvel-Eibrink, M. M., van der Velden, V. H. J., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
NO ABSTRACT
- Published
- 2021
33. Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators
- Author
-
Fornerod, M., Ma, J., Noort, S., Liu, Y., Walsh, M. P., Shi, L., Nance, S., Wang, Y., Song, G., Lamprecht, T., Easton, J., Mulder, H. L., Yergeau, D., Myers, J., Kamens, J. L., Obeng, E. A., Pigazzi, M., Jarosova, M., Kelaidi, C., Polychronopoulou, S., Lamba, J. K., Baker, S. D., Rubnitz, J. E., Reinhardt, D., van den Heuvel-Eibrink, M. M., Locatelli, Franco, Hasle, H., Klco, J. M., Downing, J. R., Zhang, J., Pounds, S., Zwaan, C. M., Gruber, T. A., Locatelli F. (ORCID:0000-0002-7976-3654), Fornerod, M., Ma, J., Noort, S., Liu, Y., Walsh, M. P., Shi, L., Nance, S., Wang, Y., Song, G., Lamprecht, T., Easton, J., Mulder, H. L., Yergeau, D., Myers, J., Kamens, J. L., Obeng, E. A., Pigazzi, M., Jarosova, M., Kelaidi, C., Polychronopoulou, S., Lamba, J. K., Baker, S. D., Rubnitz, J. E., Reinhardt, D., van den Heuvel-Eibrink, M. M., Locatelli, Franco, Hasle, H., Klco, J. M., Downing, J. R., Zhang, J., Pounds, S., Zwaan, C. M., Gruber, T. A., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Genomic characterization of pediatric patients with acute myeloid leukemia (AML) has led to the discovery of somatic mutations with prognostic implications. Although gene-expression profiling can differentiate subsets of pediatric AML, its clinical utility in risk stratification remains limited. Here, we evaluate gene expression, pathogenic somatic mutations, and outcome in a cohort of 435 pediatric patients with a spectrum of pediatric myeloid-related acute leukemias for biological subtype discovery. This analysis revealed 63 patients with varying immunophenotypes that span a T-lineage and myeloid continuum designated as acute myeloid/T-lymphoblastic leukemia (AMTL). Within AMTL, two patient subgroups distinguished by FLT3-ITD and PRC2 mutations have different outcomes, demonstrating the impact of mutational composition on survival. Across the cohort, variability in outcomes of patients within isomutational subsets is influenced by transcriptional identity and the presence of a stem cell-like gene-expression signature. Integration of gene expression and somatic mutations leads to improved risk stratification. SIGNIFICANCE: Immunophenotype and somatic mutations play a significant role in treatment approach and risk stratification of acute leukemia. We conducted an integrated genomic analysis of pediatric myeloid malignancies and found that a combination of genetic and transcriptional readouts was superior to immunophenotype and genomic mutations in identifying biological subtypes and predicting outcomes. This article is highlighted in the In This Issue feature, p. 549.
- Published
- 2021
34. TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study
- Author
-
Meijer, A. J.M., Diepstraten, F. A., Langer, T., Broer, L., Domingo, I. K., Clemens, E., Uitterlinden, A. G., de Vries, A. C.H., van Grotel, M., Vermeij, W. P., Ozinga, R. A., Binder, H., Byrne, J., van Dulmen-den Broeder, E., Garrè, M. L., Grabow, D., Kaatsch, P., Kaiser, M., Kenborg, L., Winther, J. F., Rechnitzer, C., Hasle, H., Kepak, T., Kepakova, K., Tissing, W. J.E., van der Kooi, A. L.F., Kremer, L. C.M., Kruseova, J., Pluijm, S. M.F., Kuehni, C. E., van der Pal, H. J.H., Parfitt, R., Spix, C., Tillmanns, A., Deuster, D., Matulat, P., Calaminus, G., Hoetink, A. E., Elsner, S., Gebauer, J., Haupt, R., Lackner, H., Blattmann, C., Neggers, S. J.C.M.M., Rassekh, S. R., Wright, G. E.B., Brooks, B., Nagtegaal, A. P., Drögemöller, B. I., Ross, C. J.D., Meijer, A. J.M., Diepstraten, F. A., Langer, T., Broer, L., Domingo, I. K., Clemens, E., Uitterlinden, A. G., de Vries, A. C.H., van Grotel, M., Vermeij, W. P., Ozinga, R. A., Binder, H., Byrne, J., van Dulmen-den Broeder, E., Garrè, M. L., Grabow, D., Kaatsch, P., Kaiser, M., Kenborg, L., Winther, J. F., Rechnitzer, C., Hasle, H., Kepak, T., Kepakova, K., Tissing, W. J.E., van der Kooi, A. L.F., Kremer, L. C.M., Kruseova, J., Pluijm, S. M.F., Kuehni, C. E., van der Pal, H. J.H., Parfitt, R., Spix, C., Tillmanns, A., Deuster, D., Matulat, P., Calaminus, G., Hoetink, A. E., Elsner, S., Gebauer, J., Haupt, R., Lackner, H., Blattmann, C., Neggers, S. J.C.M.M., Rassekh, S. R., Wright, G. E.B., Brooks, B., Nagtegaal, A. P., Drögemöller, B. I., and Ross, C. J.D.
- Abstract
In children with cancer, the heterogeneity in ototoxicity occurrence after similar treatment suggests a role for genetic susceptibility. Using a genome-wide association study (GWAS) approach, we identified a genetic variant in TCERG1L (rs893507) to be associated with hearing loss in 390 non-cranial irradiated, cisplatin-treated children with cancer. These results were replicated in two independent, similarly treated cohorts (n = 192 and 188, respectively) (combined cohort: P = 5.3 × 10−10, OR 3.11, 95% CI 2.2–4.5). Modulating TCERG1L expression in cultured human cells revealed significantly altered cellular responses to cisplatin-induced cytokine secretion and toxicity. These results contribute to insights into the genetic and pathophysiological basis of cisplatin-induced ototoxicity.
- Published
- 2021
35. Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia
- Author
-
Blink, M, Buitenkamp, T D, van den Heuvel-Eibrink, M M, Danen-van Oorschot, A A, de Haas, V, Reinhardt, D, Klusmann, J-H, Zimmermann, M, Devidas, M, Carroll, A J, Basso, G, Pession, A, Hasle, H, Pieters, R, Rabin, K R, Izraeli, S, and Zwaan, C M
- Published
- 2011
- Full Text
- View/download PDF
36. HEMATOPOIETIC STEM CELL TRANSPLANTATION FOLLOWING CONDITIONING WITH BUSULFAN, CYCLOPHOSPHAMIDE AND MELPHALAN IN CHILDREN WITH THERAPY RELATED MYELODYSPLASTIC SYNDROME: PH-P589
- Author
-
Yoshimi, A., Ammann, R., Truckenmüller, W., De Moerloose, B., Dworzak, M., Hasle, H., Schmugge, M., Starý, J., van den Heuvel-Eibrink, M., Zecca, M., Masetti, R., Noellke, P., Locatelli, F., Niemeyer, C., and Strahm, B.
- Published
- 2014
37. Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome
- Author
-
Klusmann, J H, Reinhardt, D, Hasle, H, Kaspers, G J, Creutzig, U, Hahlen, K, van den Heuvel-Eibrink, M M, and Zwaan, C M
- Published
- 2007
- Full Text
- View/download PDF
38. Second allogeneic hematopoietic stem cell transplantation (HSCT) results in outcome similar to that of first HSCT for patients with juvenile myelomonocytic leukemia
- Author
-
Yoshimi, A, Mohamed, M, Bierings, M, Urban, C, Korthof, E, Zecca, M, Sykora, K-W, Duffner, U, Trebo, M, Matthes-Martin, S, Sedlacek, P, Klingebiel, T, Lang, P, Führer, M, Claviez, A, Wössmann, W, Pession, A, Arvidson, J, O'Marcaigh, A S, van den Heuvel-Eibrink, M M, Starý, J, Hasle, H, Nöllke, P, Locatelli, F, and Niemeyer, C M
- Published
- 2007
- Full Text
- View/download PDF
39. Synonymous GATA2 mutations result in selective loss of mutated RNA and are common in patients with GATA2 deficiency
- Author
-
Kozyra, E., Pastor, V., Lefkopoulos, S., Sahoo, S., Busch, H., Voss, R., Erlacher, M., Lebrecht, D., Szvetnik, E., Hirabayashi, S., Pasaulienė, R., Pedace, L., Tartaglia, M., Klemann, C., Metzger, P., Boerries, M., Catala, A., Hasle, H., de Haas, V., Kállay, K., Masetti, R., Moerloose, B., Dworzak, M., Schmugge, M., Smith, O., Starý, J., Mejstrikova, E., Ussowicz, M., Morris, E., Singh, P., Collin, M., Dereka, M., Göhring, G., Flotho, C., Strahm, B., Locatelli, F., Niemeyer, C., Trompouki, E., Wlodarski, M., and EWOG-MDS, W.
- Abstract
Deficiency of the transcription factor GATA2 is a highly penetrant genetic disorder predisposing to myelodysplastic syndromes (MDS) and immunodeficiency. It has been recognized as the most common cause underlying primary MDS in children. Triggered by the discovery of a recurrent synonymous GATA2 variant, we systematically investigated 911 patients with phenotype of pediatric MDS or cellular deficiencies for the presence of synonymous alterations in GATA2. In total, we identified nine individuals with five heterozygous synonymous mutations: c.351C>G, p.T117T (N = 4); c.649C>T, p.L217L; c.981G>A, p.G327G; c.1023C>T, p.A341A; and c.1416G>A, p.P472P (N = 2). They accounted for 8.2% (9/110) of cases with GATA2 deficiency in our cohort and resulted in selective loss of mutant RNA. While for the hotspot mutation (c.351C>G) a splicing error leading to RNA and protein reduction was identified, severe, likely late stage RNA loss without splicing disruption was found for other mutations. Finally, the synonymous mutations did not alter protein function or stability. In summary, synonymous GATA2 substitutions are a new common cause of GATA2 deficiency. These findings have broad implications for genetic counseling and pathogenic variant discovery in Mendelian disorders.
- Published
- 2020
40. Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents : ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
- Author
-
Pearson, ADJ, Zwaan, C.M., Kolb, EA, Karres, D, Guillot, J, Kim, SY, Marshall, L, Tasian, SK, Smith, M, Cooper, T, Adamson, PC, Barry, E, Benettaib, B, Binlich, F, Borgman, A, Brivio, E, Capdeville, R, Delgado, D, Faller, DV, Fogelstrand, L, Fraenkel, PG, Hasle, H, Heenen, D, Kaspers, G, Kieran, M, Klusmann, JH, Lesa, G, Ligas, F, Mappa, S, Mohamed, H, Moore, A, Morris, J, Nottage, K, Reinhardt, D, Scobie, N, Simko, S, Winkler, T, Norga, K, Reaman, G, Vassal, G, Pediatric surgery, CCA - Cancer Treatment and quality of life, and Pediatrics
- Subjects
Paediatric oncology ,Medizin ,Drug development ,Paediatric Strategy Forum ,Human medicine ,Cancer therapeutics ,Acute myeloid leukaemia - Abstract
Purpose: The current standard-of-care for front-line therapy for acute myeloid leukaemia (AML) results in short-term and long-term toxicity, but still approximately 40% of children relapse. Therefore, there is a major need to accelerate the evaluation of innovative medicines, yet drug development continues to be adult-focused. Furthermore, the large number of competing agents in rare patient populations requires coordinated prioritisation, within the global regulatory framework and cooperative group initiatives. Methods: The fourth multi-stakeholder Paediatric Strategy Forum focused on AML in children and adolescents. Results: CD123 is a high priority target and the paediatric development should be accelerated as a proof-of-concept. Efforts must be coordinated, however, as there are a limited number of studies that can be delivered. Studies of FLT3 inhibitors in agreed paediatric investigation plans present challenges to be completed because they require enrolment of a larger number of patients than actually exist. A consensus was developed by industry and academia of optimised clinical trials. For AML with rare mutations that are more frequent in adolescents than in children, adult trials should enrol adolescents and when scientifically justified, efficacy data could be extrapolated. Methodologies and definitions of minimal residual disease need to be standardised internationally and validated as a new response criterion. Industry supported, academic sponsored platform trials could identify products to be further developed. The Leukaemia and Lymphoma Society PedAL/EUpAL initiative has the potential to be a major advance in the field. Conclusion: These initiatives continue to accelerate drug development for children with AML and ultimately improve clinical outcomes. (C) 2020 Elsevier Ltd. All rights reserved.
- Published
- 2020
41. Wilms' tumor 1 mutation accumulated during therapy in acute myeloid leukemia: biological and clinical implications
- Author
-
Nyvold, C G, Stentoft, J, Brændstrup, K, Melsvik, D, Moestrup, S K, Juhl-Christensen, C, Hasle, H, and Hokland, P
- Published
- 2006
- Full Text
- View/download PDF
42. Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset
- Author
-
Langer, T. (Thomas), Clemens, E. (Eva), Broer, L. (Linda), Maier, L. (Lara), Uitterlinden, A.G. (André), Vries, A.C.H. (Andrica) de, Grotel, M. (Martine) van, Pluijm, S.F.M. (Saskia F.M.), Binder, H. (Harald), Mayer, B. (Benjamin), von dem Knesebeck, A. (Annika), Byrne, J. (Julianne), Dulmen-den Broeder, E. (Eline) van, Crocco, M. (Marco), Grabow, D. (Desiree), Kaatsch, P. (Peter), Kaiser, M. (Melanie), Spix, C. (Claudia), Kenborg, L. (Line), Winther, J.F. (Jeanette F.), Rechnitzer, C. (Catherine), Hasle, H. (Henrik), Kepak, T. (Tomas), Kooi, A.L.F. (Anne-Lotte) van der, Kremer, L.C.M. (Leontien), Kruseova, J. (Jarmila), Bielack, S. (Stefan), Sorg, B. (Benjamin), Hecker-Nolting, S. (Stefanie), Kuehni, C. (Claudia), Ansari, M. (Marc), Kompis, M. (Martin), van der Pal, H.J. (Heleen J.), Parfitt, R. (Ross), Deuster, D. (Dirk), Matulat, P. (Peter), Tillmanns, A. (Amelie), Tissing, W.J.E. (Wim), Beck, J.D. (Jörn D.), Elsner, S. (Susanne), am Zehnhoff-Dinnesen, A. (Antoinette), Heuvel-Eibrink, M.M. (Marry) van den, Zolk, O. (Oliver), Langer, T. (Thomas), Clemens, E. (Eva), Broer, L. (Linda), Maier, L. (Lara), Uitterlinden, A.G. (André), Vries, A.C.H. (Andrica) de, Grotel, M. (Martine) van, Pluijm, S.F.M. (Saskia F.M.), Binder, H. (Harald), Mayer, B. (Benjamin), von dem Knesebeck, A. (Annika), Byrne, J. (Julianne), Dulmen-den Broeder, E. (Eline) van, Crocco, M. (Marco), Grabow, D. (Desiree), Kaatsch, P. (Peter), Kaiser, M. (Melanie), Spix, C. (Claudia), Kenborg, L. (Line), Winther, J.F. (Jeanette F.), Rechnitzer, C. (Catherine), Hasle, H. (Henrik), Kepak, T. (Tomas), Kooi, A.L.F. (Anne-Lotte) van der, Kremer, L.C.M. (Leontien), Kruseova, J. (Jarmila), Bielack, S. (Stefan), Sorg, B. (Benjamin), Hecker-Nolting, S. (Stefanie), Kuehni, C. (Claudia), Ansari, M. (Marc), Kompis, M. (Martin), van der Pal, H.J. (Heleen J.), Parfitt, R. (Ross), Deuster, D. (Dirk), Matulat, P. (Peter), Tillmanns, A. (Amelie), Tissing, W.J.E. (Wim), Beck, J.D. (Jörn D.), Elsner, S. (Susanne), am Zehnhoff-Dinnesen, A. (Antoinette), Heuvel-Eibrink, M.M. (Marry) van den, and Zolk, O. (Oliver)
- Abstract
Genetic association studies suggest a genetic predisposition for cisplatin-induced ototoxicity. Among other candidate genes, thiopurine methyltransferase (TPMT) is considered a critical gene for susceptibility to cisplatin-induced hearing loss in a pharmacogenetic guideline. The PanCareLIFE cross-sectional cohort study evaluated the genetic associations in a large pan-European population and assessed the diagnostic accuracy of the genetic markers. 1,112 pediatric cancer survivors who had provided biomaterial for genotyping were screened for participation in the pharmacogenetic association study. 900 participants qualified for inclusion. Based on the assessment of original audiograms, patients were assigned to three phenotype categories: no, minor, and clinically relevant hearing loss. Fourteen variants in eleven candidate genes (ABCC3, OTOS, TPMT, SLC22A2, NFE2L2, SLC16A5, LRP2, GSTP1, SOD2, WFS1, and ACYP2) were genotyped. The genotype and phenotype data represent a resource for conducting meta-analyses to derive a more precise pooled estimate of the effects of genes on the risk of hearing loss due to platinum treatment.
- Published
- 2020
- Full Text
- View/download PDF
43. Synonymous GATA2 mutations result in selective loss of mutated RNA and are common in patients with GATA2 deficiency
- Author
-
Kozyra, E. J., Pastor, V. B., Lefkopoulos, S., Sahoo, S. S., Busch, H., Voss, R. K., Erlacher, M., Lebrecht, D., Szvetnik, E. A., Hirabayashi, S., Pasauliene, R., Pedace, L., Tartaglia, M., Klemann, C., Metzger, P., Boerries, M., Catala, A., Hasle, H., de Haas, V., Kallay, K., Masetti, R., De Moerloose, B., Dworzak, M., Schmugge, M., Smith, O., Stary, J., Mejstrikova, E., Ussowicz, M., Morris, E., Singh, P., Collin, M., Derecka, M., Gohring, G., Flotho, C., Strahm, B., Locatelli, Franco, Niemeyer, C. M., Trompouki, E., Wlodarski, M. W., Locatelli F. (ORCID:0000-0002-7976-3654), Kozyra, E. J., Pastor, V. B., Lefkopoulos, S., Sahoo, S. S., Busch, H., Voss, R. K., Erlacher, M., Lebrecht, D., Szvetnik, E. A., Hirabayashi, S., Pasauliene, R., Pedace, L., Tartaglia, M., Klemann, C., Metzger, P., Boerries, M., Catala, A., Hasle, H., de Haas, V., Kallay, K., Masetti, R., De Moerloose, B., Dworzak, M., Schmugge, M., Smith, O., Stary, J., Mejstrikova, E., Ussowicz, M., Morris, E., Singh, P., Collin, M., Derecka, M., Gohring, G., Flotho, C., Strahm, B., Locatelli, Franco, Niemeyer, C. M., Trompouki, E., Wlodarski, M. W., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Deficiency of the transcription factor GATA2 is a highly penetrant genetic disorder predisposing to myelodysplastic syndromes (MDS) and immunodeficiency. It has been recognized as the most common cause underlying primary MDS in children. Triggered by the discovery of a recurrent synonymous GATA2 variant, we systematically investigated 911 patients with phenotype of pediatric MDS or cellular deficiencies for the presence of synonymous alterations in GATA2. In total, we identified nine individuals with five heterozygous synonymous mutations: c.351C>G, p.T117T (N = 4); c.649C>T, p.L217L; c.981G>A, p.G327G; c.1023C>T, p.A341A; and c.1416G>A, p.P472P (N = 2). They accounted for 8.2% (9/110) of cases with GATA2 deficiency in our cohort and resulted in selective loss of mutant RNA. While for the hotspot mutation (c.351C>G) a splicing error leading to RNA and protein reduction was identified, severe, likely late stage RNA loss without splicing disruption was found for other mutations. Finally, the synonymous mutations did not alter protein function or stability. In summary, synonymous GATA2 substitutions are a new common cause of GATA2 deficiency. These findings have broad implications for genetic counseling and pathogenic variant discovery in Mendelian disorders.
- Published
- 2020
44. Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I-BFM analysis of 333 children
- Author
-
Uden, T., Bertaina, A., Abrahamsson, J., Ansari, M., Balduzzi, A., Bourquin, J. -P., Gerhardt, C., Bierings, M., Hasle, H., Lankester, A., Mischke, K., Moore, A. S., Nivison-Smith, I., Pieczonka, A., Peters, C., Sedlacek, P., Reinhardt, D., Stein, J., Versluys, B., Wachowiak, J., Willems, L., Zimmermann, M., Locatelli, Franco, Sauer, M. G., Locatelli F. (ORCID:0000-0002-7976-3654), Uden, T., Bertaina, A., Abrahamsson, J., Ansari, M., Balduzzi, A., Bourquin, J. -P., Gerhardt, C., Bierings, M., Hasle, H., Lankester, A., Mischke, K., Moore, A. S., Nivison-Smith, I., Pieczonka, A., Peters, C., Sedlacek, P., Reinhardt, D., Stein, J., Versluys, B., Wachowiak, J., Willems, L., Zimmermann, M., Locatelli, Franco, Sauer, M. G., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Outcome of 333 children with acute myeloid leukaemia relapsing after a first allogeneic haematopoietic stem cell transplantation was analyzed. Four-year probability of overall survival (4y-pOS) was 14%. 4y-pOS for 122 children receiving a second haematopoietic stem cell transplantation was 31% and 3% for those that did not (P = <0·0001). Achievement of a subsequent remission impacted survival (P = <0·0001). For patients receiving a second transplant survival with or without achieving a subsequent remission was comparable. Graft source (bone marrow vs. peripheral blood stem cells, P = 0·046) and donor choice (matched family vs. matched unrelated donor, P = 0·029) positively impacted survival after relapse. Disease recurrence and non-relapse mortality at four years reached 45% and 22%.
- Published
- 2020
45. COVID-19 - Impact on Childhood Haematology Patients
- Author
-
Wolfs, T, Attarbaschi, A, Balduzzi, A, Bernardo, M, Bomken, S, Borkhardt, A, Bourquin, J, Dufour, C, Gennery, A, Grainger, J, Hasle, H, Hrusak, O, Izraeli, S, Mechinaud, F, Trka, J, Vormoor, J, Wolfs, Tom F W, Attarbaschi, Andishe, Balduzzi, Adriana, Bernardo, Maria Ester, Bomken, Simon, Borkhardt, Arndt, Bourquin, Jean-Pierre, Dufour, Carlo, Gennery, Andrew, Grainger, John, Hasle, Henrik, Hrusak, Ondrej, Izraeli, Shai, Mechinaud, Francoise, Trka, Jan, Vormoor, Josef, Wolfs, T, Attarbaschi, A, Balduzzi, A, Bernardo, M, Bomken, S, Borkhardt, A, Bourquin, J, Dufour, C, Gennery, A, Grainger, J, Hasle, H, Hrusak, O, Izraeli, S, Mechinaud, F, Trka, J, Vormoor, J, Wolfs, Tom F W, Attarbaschi, Andishe, Balduzzi, Adriana, Bernardo, Maria Ester, Bomken, Simon, Borkhardt, Arndt, Bourquin, Jean-Pierre, Dufour, Carlo, Gennery, Andrew, Grainger, John, Hasle, Henrik, Hrusak, Ondrej, Izraeli, Shai, Mechinaud, Francoise, Trka, Jan, and Vormoor, Josef
- Published
- 2020
46. Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I-BFM analysis of 333 children
- Author
-
Uden, T, Bertaina, A, Abrahamsson, J, Ansari, M, Balduzzi, A, Bourquin, J, Gerhardt, C, Bierings, M, Hasle, H, Lankester, A, Mischke, K, Moore, A, Nivison-Smith, I, Pieczonka, A, Peters, C, Sedlacek, P, Reinhardt, D, Stein, J, Versluys, B, Wachowiak, J, Willems, L, Zimmermann, M, Locatelli, F, Sauer, M, Uden, Theodor, Bertaina, Alice, Abrahamsson, Jonas, Ansari, Marc, Balduzzi, Adriana, Bourquin, Jean-Pierre, Gerhardt, Corinne, Bierings, Marc, Hasle, Henrik, Lankester, Arjan, Mischke, Kirsten, Moore, Andrew S, Nivison-Smith, Ian, Pieczonka, Anna, Peters, Christina, Sedlacek, Petr, Reinhardt, Dirk, Stein, Jerry, Versluys, Birgitta, Wachowiak, Jacek, Willems, Leen, Zimmermann, Martin, Locatelli, Franco, Sauer, Martin G, Uden, T, Bertaina, A, Abrahamsson, J, Ansari, M, Balduzzi, A, Bourquin, J, Gerhardt, C, Bierings, M, Hasle, H, Lankester, A, Mischke, K, Moore, A, Nivison-Smith, I, Pieczonka, A, Peters, C, Sedlacek, P, Reinhardt, D, Stein, J, Versluys, B, Wachowiak, J, Willems, L, Zimmermann, M, Locatelli, F, Sauer, M, Uden, Theodor, Bertaina, Alice, Abrahamsson, Jonas, Ansari, Marc, Balduzzi, Adriana, Bourquin, Jean-Pierre, Gerhardt, Corinne, Bierings, Marc, Hasle, Henrik, Lankester, Arjan, Mischke, Kirsten, Moore, Andrew S, Nivison-Smith, Ian, Pieczonka, Anna, Peters, Christina, Sedlacek, Petr, Reinhardt, Dirk, Stein, Jerry, Versluys, Birgitta, Wachowiak, Jacek, Willems, Leen, Zimmermann, Martin, Locatelli, Franco, and Sauer, Martin G
- Abstract
Outcome of 333 children with acute myeloid leukaemia relapsing after a first allogeneic haematopoietic stem cell transplantation was analyzed. Four-year probability of overall survival (4y-pOS) was 14%. 4y-pOS for 122 children receiving a second haematopoietic stem cell transplantation was 31% and 3% for those that did not (P = <0·0001). Achievement of a subsequent remission impacted survival (P = <0·0001). For patients receiving a second transplant survival with or without achieving a subsequent remission was comparable. Graft source (bone marrow vs. peripheral blood stem cells, P = 0·046) and donor choice (matched family vs. matched unrelated donor, P = 0·029) positively impacted survival after relapse. Disease recurrence and non-relapse mortality at four years reached 45% and 22%.
- Published
- 2020
47. Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset
- Author
-
Langer, T, Clemens, Eva, Broer, Linda, Maier, L, Uitterlinden, André, Vries, ACH, van Grotel, Martine, Pluijm, Saskia F.M., Binder, H, Mayer, Benjamin, von dem Knesebeck, A, Byrne, J, van Dulmen-den Broeder, E, Crocco, M, Grabow, D, Kaatsch, P, Kaiser, M, Spix, C, Kenborg, L, Winther, JF, Rechnitzer, C, Hasle, H, Kepak, T, Kooi, Anne-Lotte, Kremer, LC, Kruseova, J, Bielack, S, Sorg, B, Hecker-Nolting, S, Kuehni, CE, Ansari, M, Kompis, M, van der Pal, HJ, Parfitt, R, Deuster, D, Matulat, P, Tillmanns, A, Tissing, WJ, Beck, JD, Elsner, S, am Zehnhoff-Dinnesen, A, Eibrink, Marry, Zolk, O, Langer, T, Clemens, Eva, Broer, Linda, Maier, L, Uitterlinden, André, Vries, ACH, van Grotel, Martine, Pluijm, Saskia F.M., Binder, H, Mayer, Benjamin, von dem Knesebeck, A, Byrne, J, van Dulmen-den Broeder, E, Crocco, M, Grabow, D, Kaatsch, P, Kaiser, M, Spix, C, Kenborg, L, Winther, JF, Rechnitzer, C, Hasle, H, Kepak, T, Kooi, Anne-Lotte, Kremer, LC, Kruseova, J, Bielack, S, Sorg, B, Hecker-Nolting, S, Kuehni, CE, Ansari, M, Kompis, M, van der Pal, HJ, Parfitt, R, Deuster, D, Matulat, P, Tillmanns, A, Tissing, WJ, Beck, JD, Elsner, S, am Zehnhoff-Dinnesen, A, Eibrink, Marry, and Zolk, O
- Published
- 2020
48. Effect on Parental Distress of a Home-based Psychological Intervention for Families of Children with Cancer (FAMOS):A Nationwide Randomized Controlled Trial
- Author
-
Kazak, A. E., Andersen, E. W., Belmonte, F., Johansen, C., Schmiegelow, K., Winther, J. F., Wehner, P. S., Hasle, H., Rosthoj, S., Bidstrup, P. E., and Salem, H.
- Published
- 2019
49. Novel mutation of the LPIN2 gene in Turkish brothers with Majeed syndrome. Response to IL-1 inhibition
- Author
-
Hasle H, Kerndrup G, Fiirgaard B, Bjerre M, Herlin T, and Ferguson P
- Subjects
Pediatrics ,RJ1-570 ,Diseases of the musculoskeletal system ,RC925-935 - Published
- 2011
- Full Text
- View/download PDF
50. Long-term results in children with AML: NOPHO-AML Study Group – report of three consecutive trials
- Author
-
Lie, S O, Abrahamsson, J, Clausen, N, Forestier, E, Hasle, H, Hovi, L, Jonmundsson, G, Mellander, L, Siimes, M A, Yssing, M, Zeller, B, and Gustafsson, G
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.